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1 Summary 
The aim of the study was to identify main regulators of mitochondrial biogenesis in a 
skeletal muscle differentiation model. To investigate candidate factors we used the cytochrome c 
promoter as a representative promoter since cytochrome c levels correlate well with respiratory 
chain complexes. We chose the AMP activated kinase (AMPK) and cyclic AMP-response 
element binding protein 1 (CREB-1) as promising candidates, which could control the process of 
mitochondrial proliferation.  
To analyze whether AMPK regulates the cytochrome c promoter, a cell line stably 
expressing a constitutively active AMPKα1-CA was generated. Indeed, AMPKα1-CA kinase 
activity was found to be increased in these clones. However, AMPKα1-CA and dominant 
negative AMPKα constructs did not change cytochrome c promoter activity in reporter gene 
assays, total AMPK activity was unchanged during muscle differentiation suggesting that it is 
not involved in the regulation of mitochondrial biogenesis in this model. In contrast, the 
constitutively active CREB construct, C2/CREB, elevated cytochrome c promoter activity. This 
increased promoter activity was diminished in the presence of a dominant negative CREB (A-
CREB) construct showing that CREB-1 directly activates the cytochrome c promoter. Western 
blot analysis revealed two different CREB-1 isoforms: CREB-1α and CREB-1∆. Myoblasts 
contain predominantly CREB-1∆, while myotubes have preferably the CREB-1α isoform. The 
phosphorylation state of these isoforms changed in parallel with their protein levels suggesting a 
functional isoform switch during differentiation. Two appropriate, alternatively spliced isoforms 
of CREB-1 mRNA were found but their ratio did not change during differentiation. This 
suggests that posttranslational modifications and/or recruitment of the CREB-1 isoforms by other 
factors of the transcriptional complex play a dominant role in determining their cellular levels. 
To elucidate, which upstream factors regulate the activity of CREB-1, kinase and phosphatase 
inhibitors were used. A PKA activator and two phosphatase inhibitors increased the 
phosphorylation of CREB-1 at Ser-133, which is thought to be necessary for its activation. 
Furthermore, Cyclosporin A not only enhanced phosphorylation of CREB-1, but also the 
cytochrome c promoter activity. Therefore, it is likely that PP2B (calcineurin) regulates the 
phosphorylation of CREB-1 during muscle differentiation. Intracellular resting calcium levels 
were found to be smaller in myotubes compared to myoblasts, thus changes in steady-state 
calcium levels seem not to be a key regulator of mitochondrial biogenesis in muscle cells. 
In summary, these data indicate that phosphorylation and an isoform switch of CREB-1 
could play a major role in the regulation of cytochrome c promoter and thus mitochondrial 
biogenesis during muscle differentiation.       *** 
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Das Ziel der vorliegenden Arbeit war es, wichtige Regulatoren der mitochondrialen 
Biogenese in einem Skelettmuskel-Differenzierungsmodell zu identifizieren. Zur Untersuchung 
relevanter Faktoren wurde repräsentativ der Cytochrom c-Promotor verwendet, da der 
Cytochrom c-Gehalt mit dem Gehalt der Atmungskettenkomplexe korreliert. Das Enzym AMPK 
(AMP activated kinase) und CREB-1 (cyclic AMP-response element binding protein 1) wurden 
als vielversprechende Kandidaten bei der Regulation der mitochondrialen Proliferation 
ausgewählt. 
Zur Untersuchung des regulatorischen Einflusses von AMPK auf den Cytochrom c-
Promotor wurde eine Zelllinie generiert, die stabil eine konstitutiv aktive AMPKα1-CA 
exprimiert. Tatsächlich zeigten diese Klone eine erhöhte konstitutiv aktive Kinase-Aktivität. In 
Reporter-Genassays wurde dennoch keine durch AMPKα1-CA oder dominant negativen 
AMPKα-Konstrukts veränderte Cytochrom c-Promotor-Aktivität beobachtet, die gesamte 
Kinase-Aktivität ist während der Differenzierung unverändert geblieben, was darauf hindeutet, 
dass AMPKα1 nicht an der Regulation der mitochondrialen Biogenese in diesem Modell 
beteiligt ist. Im Gegensatz dazu erhöhte der konstitutiv aktive CREB-Konstrukt, C2/CREB, die 
Cytochrom c-Promotor-Aktivität. Diese erhöhte Promotor-Aktivität wurde in Gegenwart eines 
dominant negativen CREB-Konstrukts (A-CREB) vermindert und weist damit auf eine direkte 
Aktivierung des Cytochrom c Promotors durch CREB-1 hin. Zwei unterschiedliche CREB-
Isoformen konnten mittels Western Blot-Analysen gefunden werden: CREB-1α und CREB-1∆. 
Myoblasten enthalten vorrangig CREB-1∆, während Myotuben hauptsächlich die CREB-1α 
Isoform exprimieren. Der Phosphorylierungsstatus der beiden Isoformen veränderte sich 
entsprechend ihrer Proteinexpression. Dies deutet auf einen funktionellen Wechsel der Isoformen 
im Zuge der Differenzierung hin. Zwei entsprechende, alternativ gespleißte Isoformen der CREB 
mRNA werden nachgewiesen, deren Verhältnis sich jedoch während des 
Differenzierungsprozesses zueinander nicht änderte. Dies lässt vermuten, dass posttranslationale 
Modifikationen und/oder die Rekrutierung der CREB-1 Isoformen durch andere Faktoren des 
Transkriptionsapparates eine große Rolle bei der Regulation ihres zellulären Gehalts einnehmen. 
Um aufzuklären, welche vorgeschalteten Faktoren die Aktivität von CREB-1 aktivieren, wurden 
Kinase- und Phosphatase-Inhibitoren eingesetzt. Die Phosphorylierung von CREB-1 an der 
Position Ser-133, die für dessen Aktivierung wichtig ist, wurde durch einen PKA-Aktivator und 
zwei Phosphatase-Inhibitoren erhöht. Des Weiteren steigerte Cyclosporin A nicht nur die 
Phosphorylierung von CREB-1, sondern auch die Cytochrom c Promotor-Aktivität. Daher ist es 
wahrscheinlich, dass PP2B (Calcineurin) die Phosphorylierung von CREB-1 während der 
Muskeldifferenzierung reguliert. In Vergleich zu Myoblasten waren aber die basalen 
intrazellulären Kalziumlevels bei Myotuben geringer. Demnach scheinen Veränderungen des 
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basalen Kalziumlevels in Muskelzellen keine Schlüsselfunktion während der mitochondrialen 
Biogenese zu haben. 
 Zusammengefasst weisen diese Daten darauf hin, dass die Phosphorylierung und der 
Wechsel zwischen den CREB-1 Isoformen eine wichtige Rolle bei der Regulierung des 
Cytochrom c-Promotors und somit der mitochondrialen Biogenese bei der 
Muskeldifferenzierung einnehmen können. 
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2 Introduction 
The aim of the present work was to understand the regulation of mitochondrial biogenesis, 
which we define as an increase in mitochondrial number and/or mass [1]. The main questions in 
this field are i) how a cell can sense the need for enhanced mitochondrial mass and ii) what are 
the regulatory pathways involved in the resulting proliferation of mitochondria. To address this 
issue we chose a cell culture model: satellite mouse muscle myoblasts were differentiated to 
multinucleated myotubes, because the amount of mitochondria increases during this process [2]. 
Based on former results of our laboratory [3] we analyzed the AMP-activated kinase (AMPK) 
and the cyclic AMP response element binding protein 1 (CREB-1), since it was suggested that 
these proteins participate in the process of mitochondrial proliferation [4,5]. 
 
2.1 Mitochondria 
Mitochondria are thought to have evolved from a symbiotic relationship between aerobic 
bacteria (α-proteobacteria) and primordial anaerobic eukaryotic cells [6,7]. As the site of 
oxidative phosphorylation, these double-membrane organelles provide a highly efficient route 
for eukaryotic cells to generate ATP from energy-rich molecules. Electrons from oxidized 
substrates are transferred to oxygen, via a series of redox reactions, to generate water. In this 
process, protons are pumped from the matrix across the mitochondrial inner membrane by 
respiratory complexes I, III, and IV. When protons return to the mitochondrial matrix down their 
electrochemical gradient, ATP is synthesized via complex V (ATP synthase) [8]. Although the 
vast majority of the (1000 to 1500) mitochondrial proteins are encoded by the nuclear genome 
and imported into the mitochondria, mitochondria also maintain a genome that is essential for 
their respiratory function [9]. The 16 kilobase circular mitochondrial DNA (mtDNA) genome 
contains 37 genes. Thirteen of these genes encode protein subunits of respiratory complexes I, 
III, IV, and V; only complex II is solely composed of proteins encoded by nuclear genes. 
mtDNA also encodes 22 mitochondrial tRNAs and 2 rRNAs that are essential for translation of 
mitochondrial transcripts [8]. When mitochondria were discovered, ATP synthesis and Krebs 
(citric acid) cycle were claimed to be their most important function. But besides this, 
mitochondria form the compartment for other essential metabolic pathways such as β-oxidation 
of fatty acids, urea cycle and biosynthesis of pyrimidines, amino acids, phospholipids, Fe-S 
clusters and heme [10]. In the beginning, mitochondria were thought to have a rigid morphology, 
however in the past 10 years it became clear that they form a functional reticulum whose steady-
state morphology is regulated by dynamic fission, fusion and motility events [11]. The 
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mitochondrial fusion and fission processes are controlled by a growing set of ‘mitochondria-
shaping’ proteins, which also appear to influence mitochondrial pathways of cell death, but the 
underlying mechanisms are largely unknown [12]. As mitochondria play a central role in the 
“usual daily” physiology of the cell, an increasing number of degenerative diseases are 
recognized to be produced by a failure of mitochondrial functions mentioned above [10]. 
In contrast to their vital function, several organisms are known to lack classical 
mitochondria. These include Microsporidia (e.g. Encephalitozoon cuniculi), Apicomplexa (e.g. 
Cryptosporidium parvum), Diplomonads (e.g. Giardia intestinalis), Entamoeba (e.g. Entamoeba 
histolytica) and Trichomonads (e.g. Trichomonas vaginalis). However, these organisms have 
two alternative forms of mitochondria-like organelles to carry out essential functions: the so-
called hydrogenosomes in Trichomonads, fungi and anaerobic ciliates and mitosomes in 
Microsporidia, Diplomonads, Apicomplexa and Entamoeba [6,13]. 
2.2 Biogenesis of mitochondria 
The most energy demanding organs contain the highest amount of mitochondria including 
brain, heart, skeletal muscle, brown adipose tissue (BAT) and liver. The amount of mitochondria 
changes during tissue differentiation and adaptation processes. These processes of controlled 
mitochondrial biogenesis are well studied in skeletal muscle and BAT. BAT in contrast to white 
adipose tissue (WAT) contains high numbers of mitochondria in order to perform non-shivering 
thermogenesis, which are uncoupled due to the presence of the brown-fat-specific uncoupling 
protein-1 (UCP-1). When brown adipocytes differentiate during late fetal development, they 
accumulate lipid in smaller, several vacuoles and acquire a high content of mitochondria 
compared to WAT. This mitochondrial differentiation takes place in the absence of an 
environmental thermogenic stress, and can be modeled with precursor cells differentiating into 
brown adipocytes in cell culture [14]. During cold exposure of small rodent a massive 
mitochondrial proliferation occurs in brown adipose tissue [15]. The mitochondrial mass in 
skeletal muscle increases during embryonic muscle differentiation, following the repair of adult 
muscle after injury and during endurance training [16,17]. Since the latter processes have been 
extensively investigated for decades we decided to further analyze the question how 
mitochondrial biogenesis is regulated in muscle cells. 
Mitochondrial proliferation is a unique, precisely controlled mechanism including the 
expression of nuclear encoded mitochondrial genes (NEM or NUGEM) and mtDNA encoded 
mitochondrial genes (MEM) (Figure 1). Calcium plays a crucial role in this process especially in 
muscle. When action potentials are evoked at the neuromuscular junction, muscle action 
potentials open the calcium channels of sarcoplasmatic reticulum (SR) and calcium ions bind to 
                                                                                                                                        Introduction 
troponin, thus actin filaments can interact with myosin. Besides activating contraction, calcium 
can also directly trigger the calcium/calmodulin dependent protein kinases (CaMKs) and 
probably indirectly induces AMPK, which are postulated to the activate the peroxisome 
proliferator-activated receptor (PPAR) γ coactivator 1α (PGC-1α), believed to be a master 
coactivator of MEM genes (Figure 1 and [18]).  
 
Figure 1. A scheme of mitochondrial biogenesis in muscle, fusion/fission and apoptosis [18] 
For details see text below. 
 
 Changes of the cytoplasmatic calcium concentration were shown to be very important for 
the expression of genes regulating the muscle differentiation program. The upregulation of the 
structural muscle protein α-actin was completely absent in the presence of L-type calcium 
channel inhibitors in cultivated muscle cells [19]. Intermittent exposure to the calcium ionophore 
ionomycin, or to the SR calcium channel activator caffein elevated the protein expression of δ-
aminolevulinic acid synthase (ALAS), a mitochondrial key enzyme of heme synthesis and 
COXI, the mitochondrial encoded subunit I of cytochrome oxidase complex IV. EGTA, 
suppressing the effect of ionomycin or dantrolene, which blocks the calcium channels of SR, 
hence counteracting with caffeine, strongly prevented the calcium induced expression of 
mitochondrial enzymes [20]. In addition, caffeine was shown to activate the expression of PGC-
 6
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1α and mitochondrial transcription factor A (TFAM), which is crucial for mtDNA replication 
and transcription as well as the DNA binding activity of nuclear respiratory factor-1 and 2 (NRF-
1, NRF-2), and these effects were completely inhibited with dantrolene. The elevated 
intracellular calcium concentration was thought to activate CaMKs, which could also be 
involved in the regulation of mitochondrial proliferation, since the CaMK inhibitor KN93 
diminished the caffeine induced expression of mitochondrial enzymes [21]. Cytochrome c 
mRNA levels as well as the cytochrome c promoter activity was also shown to be regulated by 
calcium mediated signals, since both were elevated with the calcium ionophore A23187 
treatment, while EGTA preincubation diminished these effects. In these studies PKC but not 
CaMKII, IV or PKA was identified as the calcium activated kinase [22]. These results suggest 
that calcium besides regulating myogenesis is necessary for the execution of mitochondrial 
biogenesis. On the other hand, Gros and colleagues showed that calcium is responsible for MHC 
(myosin heavy chain) II to MHC I fiber transition but not for altered mitochondrial enzyme 
activities upon fast to slow twitch fiber type transformation [23,24]. The authors observed a 
moderately elevated resting, intracellular calcium concentration in primary muscle cells upon 
electrostimulation [24].  
Upon muscle contraction ATP:ADP ratio may decrease, which could increase AMP levels 
via the myokinase reaction: 2 ADP↔AMP+ATP. AMP-activated protein kinase has been 
described as an AMP-sensing signal transducer. A rise of AMP levels leads to allosteric 
activation of AMPK and it phosphorylates its substrates (e.g. acetyl-CoA carboxylase, HMG-
CoA reductase) but may also trigger the function of the transcriptional co-activator PGC-1α 
(Figure 1). PGC-1α also autoregulates its own gene along with the expression of NRF-1 and 
NRF-2. These are factors activating the transcription of many nuclear genes encoding 
mitochondrial proteins. NRF-1 also induces the expression of TFAM that, along with other 
nuclear-encoded mitochondrial proteins, is imported into mitochondria by the protein import 
machinery (PIM). TFAM regulates the expression of the 13 mtDNA encoded genes of the 
respiratory chain complexes [25]. Mitochondrial proteins encoded by the nucleus as well as by 
the mtDNA are assembled to form the multi-subunit enzyme complexes performing oxygen 
consumption and ATP synthesis. CREB-1 is proposed to activate PGC-1α, as Figure 1 shows, 
CREB-1 with PGC-1α is involved in the transcription of the PGC-1α gene.  
The figure also shows that the mitochondrial phenotype is altered through fusion and 
fission events. Mitofusion-2 (Mfn-2) influences the fusion of discrete populations of 
mitochondria into a larger mitochondrial reticulum, whereas Fis 1 is a protein involved in 
organelle fission. A high mitochondrial membrane potential (∆ψ) is also associated with the 
production of reactive oxygen species (ROS) from the electron transport chain complexes 
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(ETCs). Elevated ROS levels can trigger the opening of the mitochondrial permeability transition 
pore (mtPTP) and the release of pro-apoptotic factors such as cytochrome c and apoptosis-
inducing factor (AIF). Liberation of these proteins is the primary step in the mitochondrially 
mediated apoptotic program [18].  
2.3 Rationale for studying AMPK and CREB-1 
 Former experiments in our laboratory suggested a role of AMPK and CREB-1 proteins 
regulating the proliferation of mitochondria. In these studies, luciferase reporter gene assays 
were performed in the murine muscle cell line C2F3. The promoters of three different nuclear 
encoded mitochondrial genes (cytochrome c, TFAM, COXIV) were tested to identify sequence 
elements and proteins influencing their expression. The activities of all three promoters were 
highly increased upon differentiation comparing myoblasts with differentiated myotubes, 
respectively [3]. Site directed mutagenesis of the upstream CREB-1 binding site abolished the 
activation of the cytochrome c promoter during myogenesis [3]. Cytochrome c is used as a 
marker of mitochondrial density [26,27] because the amount of cytochrome c protein correlates 
well with the mitochondrial respiratory chain protein levels [28]. The rat somatic cytochrome c 
promoter has several binding sites for transcription factors e.g. NRF-1, CREB-1/ATF-1 and Sp1 
(Figure 2). Sp1 sites were found to responsible for the cytochrome c promoter activity in 
mammalian cells transfected with cytochrome c reporter constructs [29]. In addition, both CRE 
sequences contributed to the cytochrome c promoter activation upon increased cAMP level [30]. 
Furthermore, serum induction also enhanced cytochrome c promoter activity, and mutating the 
CREB-1 or NRF-1 binding cis-elements disturbed upregulation of promoter activity, so 
phosphorylated CREB-1 and NRF-1 are suggested to be involved in this process [5]. 
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Figure 2. Schematic structure and expression of the gene of cytochrome c  
A The promoter structure of rat somatic cytochrome c is shown with the transcription factor binding sites 
thought to be important for its regulation in muscle. The cis-acting element analysis was performed by the 
Genomatix MatInspector tool [31] and those, which had matrix similarity higher than 0.8 were chosen. One 
should note that the functionality of every single element was not verified. B A simplified scheme of 
expression of cytochrome c during contractile activity in muscle cells [16]. 
 
Based on our own [3] and these results [5,30], cytochrome c was chosen as a model promoter to 
search for candidate transcription factors and their regulators, which could play a role in 
mitochondrial biogenesis during muscle differentiation.  
 Gopalakrishnan and Herzig et al. investigated the in vitro promoter activation upon cAMP 
as well as serum induction in COS and fibroblast cells, respectively [5,30]. In contrast, we have 
chosen a more physiological model of muscle differentiation, which we believe may be closer to 
the in vivo situation of mitochondrial biogenesis. The cytochrome c promoter activity was 
increased upon treatment with AICAR, a well-known activator of AMPK in myoblasts as well as 
in myotubes [3]. In addition, comparing the metabolite profiles between myoblasts, confluent 
cells and myotubes, it was found that the AMP concentration increased strikingly during the 
differentiation program [3]. These results suggested an important role of AMPK in this 
myogenic process and thus we further studied the role of AMPK. The cytochrome c promoter 
was shown to be strongly stimulated during myogenesis, since myotubes showed highly elevated 
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cytochrome c promoter activity. In order to find the cis-elements controlling the promoter during 
muscle differentiation, several deleted cytochrome c promoter constructs were analyzed in 
promoter assays. A single point mutation in the downstream CRE element abolished the basal 
promoter activity in myoblasts, but more importantly the upregulation during differentiation as 
well [3]. Nuclear proteins prepared from myoblasts and myotubes bound to the sequence of the 
downstream CRE element and anti-CREB as well as anti-P-CREB antibodies bound to this 
complex performed a supershift in myotubes [32]. As these results suggested that CREB-1 
directly activates the cytochrome c promoter, we further clarified its role in mitochondrial 
biogenesis. 
2.4 The role of AMPK in mitochondrial biogenesis  
The evolutionary conserved AMP activated kinase belongs to the Ser/Thr protein kinase 
family. It forms a heterotrimeric complex consisting of the α (63 kDa), β (38 kDa) and γ (35 
kDa) subunits [33]. In mammals, each subunit is encoded by multiple genes (α1, α2, β1, β2, γ1, 
γ2, γ3) with additional splice variants. AMP activates the kinase activity by three different 
mechanisms; it allosterically activates AMPK, triggers the upstream kinase (LKB1) to 
phosphorylate the important Thr-172 site in the α subunit of AMPK, and inhibits the 
dephosphorylation of this site by blocking a protein phosphatase. All effects of AMP are 
antagonized by high amounts of ATP emphasizing the role of AMPK as an energy sensor. 
Briefly, the major function of the kinase is to activate the catabolic, energy producing pathways, 
such as fatty acid oxidation, glycolysis, etc and inhibit anabolic, ATP consuming pathways, such 
as fatty acid synthesis or gluconeogenesis. In addition to its acute metabolic role, it is also 
believed to participate in the regulation of proteins involved in mitochondrial biogenesis, e.g. by 
upregulating the gene for NRF-1 and PGC-1α (Table 1) [34].  
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Table 1. Examples of AMPK substrates and their biological effects [34]
 
“Primary targets” are direct targets for AMPK where the phosphorylation site(s) have been identified. 
“Secondary targets” are either regulated indirectly or the direct target remains unclear. 
 
AICAR is a widely used AMPK activator. Upon chronic AICAR treatment in rats, mRNA 
and protein levels of UCP-3 (uncoupling protein 3) as well as enzyme activities of citrate 
synthase and hydroxyacyl-CoA-dehydrogenase (HADH), which are known to increase in 
proportion to mitochondrial volume, were increased in muscle [4,35], but the MHC based fiber 
type transition did not occur [4]. In another study, chronic AICAR treatment increased the 
activity of the mitochondrial enzymes citrate synthase, succinate dehydrogenase, and malate 
dehydrogenase as well as the cytochrome c and ALAS protein levels in white quadriceps [36]. β-
guanidinopropionic acid (β-GPA; 1% enriched diet), a creatine analog that is known to induce 
mitochondrial proliferation similar as in exercise training was used to activate AMPK in rat 
muscle. β-GPA treatment results in an energetic deficit with increased levels of ALAS mRNA 
and enhanced NRF-1 binding activity to the ALAS promoter sequence. Cytochrome c protein 
and mitochondrial density were also elevated upon β-GPA treatment [37].  
AICAR and β-GPA are not specific activators of AMPK, but also could activate other 
AMP-binding proteins [38] and other programs and their efficiency and specificity depends on 
their uptake [39], which restrict their usage in experiments. For this reason constitutively active 
(CA) and dominant negative (DN) AMPK constructs were created to modulate the kinase 
activity more specifically [40]. Overexpression of the AMPKα1-CA construct and AICAR were 
shown to enhance glucose transport in a rat liver epithelial cell line [41]. In addition, in H-2Kb 
mouse muscle cells, ectopic AMPKα1-CA expression increased glucose uptake and the 
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expression of the glucose transporters GLUT-1 and GLUT-4, which are suggested to regulate 
glucose transport in this cells [42]. 
Silencing AMPK expression by siRNA showed that it is also involved in GLUT-3 
mediated glucose uptake [43]. Furthermore, muscle specific transgenic mice showed that a 
dominant AMPKα2 inhibitory mutant completely blocked the hypoxia or AICAR activated 
glucose uptake in skeletal muscle, while the contraction stimulated glucose uptake was only 
partially inhibited [44]. Analyzing skeletal muscle of these mice showed that AMPKα2 
participates in the induction of CaMKIV, PGC-1α, cytochrome c [45]. Deletion of both catalytic 
subunits (α1 and α2) in mouse resulted an embryonic lethal phenotype [34]. However, α1−/− KO 
showed no defect in glucose homeostasis, while α2−/− KO exhibited high plasma glucose level, 
low plasma insulin level, reduced muscle glycogen synthesis and insulin resistance [46]. AICAR 
induced glucose uptake was abolished in skeletal muscle of α2−/− KO mice, which was not 
visible in mice deficient in the subunit α1, although in none of the knock-out mice, glucose 
uptake induced by the contraction was affected [47]. In conclusion, the function of AMPK in 
vivo is not clear yet and there are many unsolved details how this kinase regulates cell 
metabolism, especially the process of mitochondrial biogenesis. 
2.5 CREB-1 protein: a point of convergence 
The cyclic AMP (cAMP) response element (CRE)-binding protein 1 (CREB-1) belongs to 
the bZIP (basic leucine zipper) transcription factor superfamily and comprises a subcategory 
including CREB-1, CREM (cAMP response element modulator) and ATF-1 (activating 
transcription factor 1) [48]. CREB-2 (ATF-4) [49], CREB-3 (Luman) [50], CREB-4 [51] and 
CREB-5 (CRE-BPa) [52] have also been identified but they do not belong to the classical 
CREB-1 family. The CREB-1 protein contains two glutamine rich domains called Q1 and 
Q2/CAD (constitutive active domain) (Figure 3). The Q2/CAD domain interacts with the basal 
transcription factor TAF130, a component of TFIID complex and TFIIB. The KID (kinase 
inducible domain) lies between these domains containing Ser-133, the phosphorylation of which 
is a prerequisite for the transcriptional activity of CREB-1. This domain has other amino acids 
(e.g. Ser-142), which could be also phosphorylated but their functions are not clear yet. The C-
terminal bZIP domain is rich in the positively charged basic amino acids lysine, arginine and 
leucine. The heptad repeat of leucine forms the so-called Leucine zipper motif connecting two 
monomers. The CREB-1 family members can form homo- or heterodimers, but in the latter case 
they are restricted to heterodimerize with each other and not with other bZIP transcription 
factors, with the exception of C/EBPβ.  
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Figure 3. The structure of CREB-1 isoforms [48] 
Exon organization of the CREB-1 gene is shown by the upper graphic, exon 5 is spliced out to form CREB-1∆ 
mRNA and exon 2 is spliced out to form CREB-1β mRNA. Black boxes indicate the translated regions. Q1 
and Q2: glutamine rich regions, α: exon 5, KID: kinase inducible domain, CAD: constitutive active domain, 
bZIP: basic leucine zipper domain. 
 
The CREB-1 gene contains 11 exons (Figure 3). By alternative splicing several isoforms of 
CREB-1 are produced; the full length CREB-1 isoform is called CREB-1 α (coding 341 amino 
acid), if the 5th (α) exon is spliced out CREB-1 ∆ (coding 327 amino acid) is formed, and if the 
2nd exon is also missing, CREB-1 β is generated (Figure 3). They are the best known CREB-1 
isoforms but their detailed function remains obscure. Alternative splicing of the gene of CREM 
creates transcriptional activators (CREM α and τ) or the repressors ICER (inducible early cAMP 
repressor) or S-CREM, while ATF-1 derived from a third gene serves as an activator of 
transcription [48].  
To increase the complexity of CREB-1 effects, it is known that the “CREB-1-
transcriptosome” differs dramatically from cell type to cell type according to the presence of 
other transcription factors, transcriptional coactivators, enhancers and silencers [53]. CREB-1 is 
localized in the nucleus and got its name due to its binding to the octamer, cis-acting CRE 
element 5´-TGACGTCA-3´, which is responsible for the reaction to increased levels of cAMP. 
The G protein coupled catecholamine receptors (GPCRs) start a signal cascade on the cell 
membrane (Figure 4). After a ligand (e.g. dopamine or norepinephrine) binds to the receptor, 
adenylate cyclase (AC) is stimulated to increase the level of cAMP, which activates protein 
kinase A (PKA), so that its catalytic subunits translocate to the nucleus and phosphorylate Ser-
133 of the CREB-1 protein. Upon Ser-133 phosphorylation, CREB-1 is activated as it recruits 
the CREB binding protein (CBP) or its paralogue p300, which are transcriptional coactivators 
with histone acetyl transferase (HAT) activity. CBP or p300 serves as a molecular bridge that 
allows transcription factors to stabilize the RNA polymerase II transcription initiation complex. 
The CREB-1-CBP/p300 complex binds to the basal transcription factors (TFIIB, TFIID) and to 
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the RNA helicase A (RHA), completing the initiation of transcription and transcriptional 
elongation can start [48].  
 
PP2B
CaMK IV
PP1
PP2A
 
Figure 4. The CREB-1 signal transduction pathway 
For details see text above. 
 
GPCRs are not the only receptors transmitting the signal for CREB-1 activation; Ca2+ channels, 
growth factor receptors (GFRs), activated RAC1 (Rho GTPase) are first sensors of cells to 
induce the transcription of genes activated by CREB-1. Other known CREB-1 phosphorylating 
kinases besides PKA are the MSK1 (Mitogen and stress activated protein kinase 1), AKT 
(Protein kinase B α), RSK (Ribosomal protein S6 kinase) and CaMK IV (Figure 4). Beside 
protein kinases, protein phosphatases are also contributing to modify the activity of CREB-1. 
Protein phosphatase 1 (PP1), 2A and 2B (calcineurin) dephosphorylate Ser-133, thus preventing 
its interaction with CPB/p300 and inhibit CREB-1 activated gene expression (Figure 4) [48].  
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CREB-1 is one of the best-characterized stimulus-induced transcription factors. CREB-1 
has pleiotropic functions as it is critical for many distinct cellular processes and it is puzzling 
how such a widely expressed transcription factor activated in many situations can facilitate so 
diverse but still so specific functions [54]. It plays a role in the control of memory, cell 
proliferation, differentiation, adaptive responses, glucose and lipid metabolism.  
Brain seems to be the best studied organ to clarify the function of CREB-1 and the protein 
is involved in the process of learning and memory, addiction, depression, anxiety [55] and even 
was reported to be modulated in suicide behavior [56]. Complete CREB-1 KO is lethal in mice, 
but not during embryogenesis but rather immediately after birth. The main cause of death is 
respiratory distress with strong reduction of nerve cell mass in corpus callosum and the anterior 
commissures but also impaired T-cell development [57]. In order to investigate the function of 
CREB-1 in the absence of CREM, which may compensate the effect of CREB-1, neuronal 
CREB-1 KO mice were crossed with CREM KO mice. The descendent animals neither have 
CREB-1 nor CREM in their brains. During development of neurons in the central nervous 
system, extensive apoptosis was found and in postnatal forebrain the hippocampus showed 
progressive neurodegeneration [58]. These results suggest that CREB-1 is essential for neuronal 
survival signal pathways. 
 Besides neuronal tissue, CREB-1 is also involved in transcriptional processes in 
adipocytes, hepatocytes and muscle. In adipocyte differentiation, it binds the promoter of several 
adipocyte specific genes such as phosphoenolpyruvate carboxykinase (PEPCK), fatty acid 
binding protein (FABP), CCAAT-enhancer binding protein β (C/EBP β) and activates the 
expression of PPAR-γ2 [59]. Upon the insulin induced differentiation of adipocytes, CREB-1 
becomes activated and, besides PPAR-γ2 and FABP, also induces the expression of GLUT-4 and 
leptin [60]. In mature adipocytes, CREB-1 regulates both the survival and apoptotic pathways 
and seems to be important as an anti-apoptotic protein [61]. In addition, CREB-1 coordinates 
hepatic lipid and glucose metabolism during fasting through induction of PGC-1α [62] and 
inhibition of PPAR-γ  [63].  
 In skeletal muscle, CREB-1 is associated with MyoD in C2.7 cells and targeted to the 
retinoblastoma (RB) gene promoter to enhance its transcription. The elevated level of RB protein 
is essential for myoblast cell cycle arrest, therefore for terminal differentiation and for survival of 
myocytes [64]. Recently it was shown that CREB-1 is also required for Wnt-directed myogenic 
gene expression and Wnt proteins could also stimulate CREB-1 mediated transcription [65].  
 Muscle differentiation is strictly dependent on the function of mitochondria [66]. CREB-
1 also controls the expression of several genes involved in the function of mitochondria. 
Mitochondrial dysfunction, i.e. complete absence of mtDNA in rho0 cells or depleting the 
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mtDNA with ethidium bromide (rho− cells) was found to activate CRE sequence containing 
promoters (c-Fos and α-inhibin). This induction was blocked by expressing CREB-1 dominant 
negative constructs suggesting a role of CREB-1 in the proliferation defects observed in these 
cells. Phosphorylation of CREB-1 at Ser-133 was increased in the presence of disturbed 
mitochondrial function and CaMKIV was identified as the CREB-1 phosphorylating upstream 
kinase [67]. The amount of cytochrome c protein was elevated and promoter activity of 
cytochrome c was increased in rho0 cells, which was again blocked by the expression of CREB-1 
dominant negative constructs. Interestingly, the authors detected an increased mitochondrial 
amount in rho0 cells and concluded that the depletion of mtDNA causes a counteracting 
stimulation of mitochondrial biogenesis [68]. In addition, mitochondrial dysfunction in 
adipocytes caused by blocking complex III induced elevated levels of triglycerides (TG) and 
CREB-1 activation was needed for this TG accumulation, which was shown to be due to the 
induction of several adipogenetic genes [69]. Taken together, mitochondrial dysfunction seems 
to cause a kind of retrograde stimulation of mitochondrial biogenesis, in which CREB-1 is also a 
key regulator.  
In hepatocytes, CREB-1 stimulates the promoter of liver carnitine palmitoyltransferase I, 
which is the rate limiting enzyme in mitochondrial fatty acid oxidation, shown by treatment with 
a cAMP analogue and PGC-1α coactivates this effect of CREB-1 [70]. PGC-1α was originally 
identified as a coactivator of PPAR-γ and a regulator of brown fat differentiation, but it turned 
out that together with PGC-1β, it is also a main regulator of mitochondrial biogenesis in muscle 
[9].  
Recently a new CREB-1 coactivator family was identified called transducers of regulated 
CREB activity (TORCs). TORC-1, 2 and 3 proteins are considered to bind the bZIP domain of 
CREB-1 and recruit it to TAFII 130, independently of the phosphorylation state of Ser-133 [71]. 
TORC function is essential for CRE-mediated gene expression induced by cAMP, calcium, 
GPCRs and the nuclear transport of TORC1 was sufficient to activate CRE dependent 
transcription [72]. TORC1 was the most potent PGC-1α activator from 10,000 screened human 
cDNAs. TORC2 and 3 also elevate PGC-1α transcription in a CREB-1 dependent manner. 
Overexpression of all the TORCs enhanced mitochondrial oxidative capacity in muscle cells, and 
all of them increased the level of cytochrome c mRNA [73]. 
Cytochrome c was the first mitochondrial gene to be studied intensively and shown to be a 
target promoter regulated by CREB-1. In quiescent fibroblasts, serum induced proliferation 
elevates mitochondrial respiration as well as the level of mRNA, protein and promoter activity of 
cytochrome c [5]. The serum induced proliferation activates the cytochrome c promoter through 
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the PGC-1 related coactivator (PRC) [74]. CREB-1 and NRF-1 bind to the PRC promoter but 
they are also required for the stimulation of the cytochrome c promoter by PRC [75].  
Against the dogma, which says that CREB-1 resides exclusively in the nucleus, 
extranucleic CREB-1 was found associated to mitochondria. Mitochondrial CREB-1 and 
phospho-CREB-1 were detected in rat forebrain and the authors suggest that they are localized in 
the mitochondrial matrix or in the inner membrane. Increased calcium levels decreased the 
phosphorylation state of mitochondrial CREB-1 meaning that calcium could regulate 
mitochondrial CREB-1 function [76]. In brain, CREB-1 and phospho-CREB-1 were partially 
colocalized with cytochrome c and in CREB-1 KO mice the phospho-CREB-1 immunoreactivity 
was completely diminished. Three different CRE elements were detected in the sequence of the 
regulatory D-loop region of mouse mtDNA and all of them were able to bind CREB-1. CREB-1 
was also shown to slightly increase ND2 and ND4 transcripts of complex I, while the dominant 
negative A-CREB protein decreased transcripts of ND5 and ND6 of complex I as well as its 
enzyme activity. The mitochondrial CREB-1 appears to regulate neuronal pro-survival effects 
because upon treatment with a mitochondrial toxin 3-nitropropionic acid, A-CREB stimulated 
the cell death and the release of cytochrome c caused by the toxin [77]. However, a more recent 
study suggests that phospho-CREB-1 immunoreactivity in neurons is the phospho-pyruvate 
dehydrogenase E1 α subunit, due to crossreactivity with the antibody against phospho-CREB-1 
[78]. Although in the latter study a mitochondrial CRE binding activity could not be shown, the 
former study found a clear CRE binding activity supershifted with an anti-CREB-1 antibody and 
even shown an in vivo interaction between the mtDNA D-loop region and CREB-1 by chromatin 
immunoprecipitation (ChIP) [77]. In conclusion, while CREB-1 involvement in the regulation of 
mtDNA is still controversial, it upregulates the promoter of cytochrome c and many other 
mitochondrial genes encoded in the nucleus directly and via enhancing coactivators, and could 
be a key factor for mitochondrial biogenesis. 
2.6 Aim of the study 
In spite of intensive investigations, many questions concerning the regulation of 
mitochondrial biogenesis have not been solved yet. Our main question was, which factors 
activate the cytochrome c promoter and thus may be involved in stimulation of mitochondrial 
proliferation. If the factors were identified, how do they control the complex process of 
mitochondrial biogenesis, where hundreds of genes have to be coordinated. Which upstream 
signals are involved in controlling these “regulator” proteins? To study these questions, muscle 
precursor cells were differentiated to multinucleated myotubes, which is accompanied by a 
marked increase of mitochondrial enzymes. 
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AMPK was the first studied candidate and cell lines expressing constitutively active 
AMPKα1 were created to investigate its role. CREB-1 and its isoform was the second factor of 
choice and its expression was analyzed at the levels of mRNA and protein, together with 
investigation of its phosphorylation status. This was followed by assessment of its activity by 
using siRNA knock-down, constitutively active and dominant negative constructs in reporter 
gene assays. 
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3 Materials and Methods 
3.1 Materials  
3.1.1 Chemicals 
All chemicals were purchased from the companies Merck, Sigma-Aldrich or Roth, unless 
otherwise specified. 
 
Coelenterazine        Biotium 
D-Luciferin         Biotium 
ExGen          Fermentas 
Fura-2 AM         TEFLabs 
Lipofectamine 2000        Invitrogen 
Metafectene         Biontex 
Mini complete® Proteaseinhibitor-Cocktail (EDTA free)   Roche 
Rp-8-CPT-cAMPS        BioLog 
Sp-5,6-DCI-cBIMPS        BioLog 
Trizol          Invitrogen 
3.1.2 Equipment 
Agarose gel chamber   Easycast   Owl Scientific  
Cell counter    CASY®1 Modell TT   Schärfe System 
Centrifuge        Eppendorf 
Hybridisation oven       Amersham Pharmacia 
Fluorescence microscope  Axiovert 100   Zeiss 
Fluorescence microscope   Axiophot    Zeiss  
Incubators    HeraCell   Heraeus 
Liquid Scintillation Counter   LS 6500   Beckman 
Luminometer    Sirius-1   Berthold Detection Systems 
Medical X-Ray Film    Super RX   Fuji 
Microplate Reader    µQuant   BioTek Instruments 
PCR-Thermocycler   PTC-100   MJ Research Inc. 
SDS-PAGE chamber   Tall Mighty Small  Hoefer    
Spectrophotometer       Beckman  
UV-Crosslinker    UVC500   Hoefer 
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3.1.3 Organisms 
Bacterial organism    Escherichia coli DH5α [79] 
F- gyrA96 (Nalr) recA1 relA1 endA1 thi-1 hsdR17 (rk
-mk+) glnV44 deoR ∆(lacZYA-argF) U169 
[φ80d∆(lacZ)M15] 
  
Mammalian cell lines  
  C2F3  mouse muscle cell line [80] 
 C2C12  mouse muscle cell line (ATTC Number: CRL-1772) [80] 
3.1.4 Materials for cell culture  
Cell culture dishes      TPP, Costar Corning  
DMEM with Glutamax I, 4.5 g/l Glucose    Gibco BRL Cat.No. 61965-026 
DMSO, cell culture tested     Sigma Cat.No. D-4540 
FCS         PAA Cat.No. A15-043 
Horse serum       Sigma Cat.No. H 1270 
MEM Nonessential Amino Acids 100x   Gibco BRL Cat.No. 11140-035 
Na-Pyruvate 100 mM (sterile filtered)   Gibco BRL Cat.No. 11840-048 
OptiMEM       Gibco BRL Cat.No. 51985-026 
PBS        Gibco BRL Cat.No. 18912-014 
Trypsin-EDTA 0.05 % in HBSS    Gibco BRL Cat.No. 25300-054 
 
Additives to the media: 
1 mM sodium pyruvate 
1x nonessential amino acids  
1 % penicillin streptomycin  
10 % FCS for cultivating the cells, or 2 % horse serum for differentiation media 
3.1.5 Antibiotics 
End concentration 
Ampicillin   Sigma      50 µg/ml 
Carbenicillin   Sigma      50 µg/ml 
G418    PAA      700 µg/ml 
Hygromycin B  PAA/InvivoGen    700 µg/ml 
Penicillin   Gibco BRL     1 % 
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Streptomycin   Gibco BRL     1 % 
3.1.6 Materials for standard molecular biology 
3.1.6.1 Oligonucleotides 
mCREB-103-5´  5´-ACATTAGCCCAGGTATCCATGCCAG-3´ 
mCREB-396-3´  5´-GGCCTCCTTGAAAGGATTTCCCTTCG-3´ 
mCREB 418 5´  5´-GACTTATCTTCTGATGCACCAGG-3´ 
mCREB 962 3´  5´-GGTTTTCAAGCACTGCCACTC-3´ 
Oligonucleotides were synthetised by Sigma-Genosys or by Operon. 
3.1.6.2 Nucleic acids 
Vectors 
pcDNA-AMPKα1-CA     gift from Dr. Carling 
pGL3-cytochrome c-Firefly     made by Dr. Goffart 
pRL-CMV       Promega 
pRL-SV40       Promega 
pTRE2-Hyg       Clontech 
pRSETA       gift from Dr. Goffart 
pCMV        gift from Dr. Thiel 
pTRE2-Firefly      gift from Prof. Brüning 
pCMV-Flag-C2/CREB     gift from Dr. Thiel 
pEBGN-CREB      gift from Dr. Thiel 
pEBGN-K-CREB      gift from Dr. Thiel 
pCMV-A-CREB       gift from Dr. Thiel 
α-inhibin-Firefly      gift from Dr. Arnould 
siRNAs 
siRNA SMART pool against CREB-1 NM 133828   Dharmacon 
siCONTROL negative #1      Dharmacon 
siCONTROL negative pool      Dharmacon 
siCONTROL TOX       Dharmacon 
3.1.6.3 Enzymes 
Taq-Polymerase     Fermentas 
Klenow-Fragment    Fermentas 
T4-DNA-Ligase    Fermentas 
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Shrimp alkaline phosphatase   Amersham 
Lambda protein phosphatase   Upstate 
Restriction enzymes    New England Biolabs/Fermentas 
3.1.6.4 Kits  
Chroma spin columns (for DNA purification)  Clontech 
Dynabeads mRNA DIRECT Kit    Invitrogen 
ECL-Kit       PerkinElmer 
GenElute Plasmid Maxiprep Kit    Sigma 
QIAamp DNA Mini Kit     Qiagen 
QIAGEN Plasmid Midi Kit     Qiagen 
QIAEX II Gel Extraction Kit     Qiagen 
QuantiTect Reverse Transcription Kit   Qiagen 
QIAquick PCR Purification Kit    Qiagen 
Random Primed DNA-Labeling Kit     Roche 
5x Passive lysis buffer     Promega 
3.1.6.5 Radiochemicals 
α32P-ATP  5,000 Ci/mmol  Hartmann Analytics 
γ32P-dCTP  5,000 Ci/mmol  Hartmann Analytics 
3.1.6.6 Markers, dyes 
1kb-Ladder      Gibco BRL 
GeneRuler 100 bp Marker    Fermentas 
PageRuler Prestained Protein Ladder  Fermentas 
6x DNA loading dye     Fermentas 
RiboRuler RNA ladder, High range   Fermentas 
3.1.6.7 Antibodies 
First antibodies      Cat.No. Working dilution
Monoclonal anti-β-actin  Sigma-Aldrich A 1978  1:5,000 
Monoclonal anti-β-tubulin  Sigma-Aldrich T 4026   1:1,000 
Monoclonal anti-c-myc  Santa Cruz B.  sc-40   1:1,000 
Monoclonal anti-Histone H1  Santa Cruz B.  sc-8030  1:1,000 
Monoclonal anti-Myogenin (F5D) Santa Cruz B.  sc-12732  1:400 
Monoclonal anti-MHC (1F11) gift from Dr. F. Pons     1:2 (IHC) 
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Polyclonal anti-α-actinin 4  ImmunoGlobe 0042-05 1:1,000-1:3,000 
Polyclonal anti-AMPKα  Cell Signaling T. 2532   1:1,000(WB) 
           1:100 (IP) 
Polyclonal anti-AMPKα1  gift from Dr. Carling     1:50 (IP) 
Polyclonal anti-CREB-1  Cell Signaling T. 9192  1:500-1:1,000 
Polyclonal anti-CREB-1α  Santa Cruz B.  sc-58   1:1,000 
Polyclonal anti-CREB-1  Upstate  06-863   1:2,000 
Polyclonal anti-Phospho-CREB-1 Cell Signaling T. 9191   1:1,000 
 
Secondary antibodies         Cat.No.  Working dilution 
Donkey-anti-rabbit IgG-HRP  Dianova 711-035-152   1:1,000 
Goat-anti-mouse IgG-HRP  Dianova 115-035-062  1:5,000-1:10,000 
Goat-anti-mouse IgG-Cy3        1:50 
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3.2 Methods 
3.2.1 Standard molecular biology 
3.2.1.1 E. coli cultivation 
Eschericia coli DH5α strain was used as a tool for plasmid DNA amplification. Bacteria were 
inoculated from an LB-agar plate (complemented with the appropriate antibiotic) into LB 
medium (with the antibiotic) for overnight incubation with shaking at 37°C. Plasmid preparation 
was made from overnight bacterial cultures. 
LB-Medium/Agar 1 % NaCl  
   1 % bacto trypton 
   0.5 % yeast extract 
   pH 8.0 
   (1.5 % bacto agar) 
3.2.1.2 Preparation of transformation-competent E. coli 
Eschericia coli strain DH5α was streaked from −80°C frozen stock on a fresh LB plate and 
grown overnight at 37°C. A single colony was inoculated into 10 ml LB. It was grown overnight 
with shaking at 37°C. 1 ml was inoculated into 200 ml LB and shaken at 37°C until OD600=0.5. 
The flask was chilled on ice for 5 minutes and the bacteria were centrifuged for 5 minutes at 
5,500 x g. The pellet was resuspended in 80 ml ice cold Buffer 1 and incubated in ice for 5 
minutes. It was centrifuged for 5 minutes at 5,500 x g again, the pellet was resuspended in 8 ml 
ice cold Buffer 2 and chilled on ice for 15 minutes. 200 µl aliquots were made in 1.5 ml tubes, 
flash-frozen in liquid nitrogen and then stored at −80oC.  
Buffer 1   30 mM potassium acetate pH 5.8 
100 mM RbC12
10 mM CaCl2
50 mM MnC12
15 % glycerol  
Buffer 2   10 mM MOPS/KOH pH 6.5 
75 mM CaC12
10 mM RbC12
15 % glycerol 
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3.2.1.3 Plasmid DNA preparation 
Plasmid preparations were made from transformed E. coli overnight culture according to the 
manual of the Kits used. The plasmid DNA was eluted with H2O or with 10 mM Tris pH 8.0 and 
the concentration was measured spectrophotometrically at 260 nm. 
3.2.1.4 Transformation 
A 200 µl aliquot of E. coli competent bacteria was thawed on ice. Plasmid DNA was added and 
mixed gently. They were incubated on ice for 10 minutes followed by a heat shock for 1 minute 
at 42°C. The bacteria were incubated for 5 minutes on ice, 1 ml LB was added and shaken for 1 
hour at 37°C. The whole bacterial supernatant or a part of it was plated on LB-agar (with 
antibiotic) and incubated overnight at 37°C. 
3.2.1.5 Glycerol stock 
For long time storage of transformed bacteria, 15 % glycerol stocks were made in LB medium 
and stored at –80°C. After storage the bacteria were scraped with a sterile loop onto LB-agar 
completed with the appropiate antibiotic and incubated overnight at 37°C. 
3.2.1.6 Nucleic acid gel electrophoresis 
The separation of DNA fragments were analyzed in 1-2 % agarose gels in 1x TAE buffer with 
0.5 µg/ml ethidium bromide. 6x DNA loading dye (Fermentas) or 10x DNA loading dye was 
added to the probes. A molecular weight marker was also loaded to determine the molecular size 
of the fragments. The samples were run at 80-90 V for 30-40 minutes and were documented 
using a CCD video camera. 
50x TAE    2 M Tris 
1 M acetic acid 
     50 mM EDTA pH 8.0 
10x DNA loading dye  0.06 % bromophenol blue 
     0.06 % xylene cyanol 
     50 % glycerol 
     20 mM Na-EDTA pH 8.0 
     180 mM Tris pH 7.5 
3.2.2 Principle of Tet-Off system 
In the Tet-Off system, the transactivator protein (tTA) consists of a tetracycline repressor (tetR) 
and a VP16 activation domain, working as a tetracycline sensitive activator [81] (Figure 5). It 
binds on the TRE sequence of the second plasmid with the gene of interest and activates its 
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transcription. In the presence of tetracycline (Tet) or its derivative doxycycline (Dox), the 
transactivator protein binds the ligand resulting in the inhibition of transcription. The system got 
its name since in the presence of Tet, the transcription of the gene of interest is “switched off”. 
The ligand is present in the phase of creating stable cell lines and removing it induces the 
expression of the gene of interest.  
 
 
Figure 5. The principle of Tet-Off system  
The transactivator (tTA) protein is continuously expressed driven by the CMV promoter. It binds to the TRE 
sequence of the plasmid containing the gene of interest and enhances the transcription of the gene in the 
absence of Tetracycline or Doxycycline. In the presence of Tet or Dox the tTA protein is inhibited to bind to 
the TRE sequence, which causes the lack of transcription. 
 
3.2.3 Cloning of rat AMPKα1-CA into pTRE2-Hyg vector 
The DNA sequence of the AMPKα1-CA was cloned into the mammalian expression vector 
pTRE2Hyg, which has a Tetracycline response (TRE) promoter and resistance genes against 
Ampicillin and Hygromycin B. The pTRE2Hyg vector was digested with PvuII, purified with the 
QIAquick PCR Purification Kit and digested with SalI enzymes (Appendix Figure 1 A and B). 
To diminish self-ligation the free phosphate group was dephosphorylated by SAP phosphatase 
and the vector was purified from agarose gel. The pcDNA3-AMPKα1-CA construct was 
digested first with KpnI enzyme cutting out AMPKα1-CA from the pcDNA3 vector, purified 
with the QIAquick PCR Purification Kit (Appendix Figure 1A) and the overhanging nucleotides 
were filled up using Klenow enzyme to generate blunt ends. The AMPKα1-CA blunt ended 
fragment was purified from agarose gel and digested with XhoI enzyme (Appendix Figure 1B) 
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followed by a gel purification by QIAEX II Gel Extraction Kit. The PvuII/SalI cut pTRE2Hyg 
vector and the XhoI/blunt ended AMPKα1-CA fragments were ligated with T4 DNA ligase for 1 
hour at 22°C according to the blunt ends (PvuII and filled KpnI) and the compatible sticky ends 
(SalI and XhoI). The ligation mixture was transformed into competent E. coli DH5α bacteria and 
several growing colonies were checked with restriction digestion. Test digestions verified that 
AMPKα1-CA was integrated into the pTRE2Hyg vector. The sequence was verified by 
sequencing the AMPKα1-CA region starting from the commercially available pTRE2-Hyg 
primers. PstI enzyme cut the pTRE2Hyg-AMPKα1-CA construct into two fragments, which are 
4324 bp and 1988 bp (Appendix Figure 1C) in contrast to the empty vector, which is linearized 
having only one PstI site. The cloned AMPKα1-CA insert contains two HindIII restriction sites. 
HindIII digestion of the pTRE2Hyg-AMPKα1-CA construct resulted in three fragments with the 
length of 5205, 876 and 231 bp (Appendix Figure 1D).  
3.2.3.1 Cultivation 
The murine muscle cell lines (C2C12 and C2F3) were cultivated at 37°C, 5 % CO2 and in 
humidified air on cell culture plates or flasks. Both cell lines were routinely cultivated in 
DMEM+10 % FCS. The cells were split on every second or third day (cells should have not been 
more confluent than 85 %) and seeded 2-3 x 105 cells on a 10 cm cell culture dish for two days. 
Cells were detached with trypsin, centrifuged at 200 x g and resuspended in PBS for counting. 
Differentiation was induced by growning the myoblasts to 100 % confluency followed by 
changing growing medium (DMEM+10 % FCS) to differentiation medium (DMEM+2 % horse 
serum). For the myotubes, the medium was changed every day and experiments were done with 
myotubes, which had been cultivated in DMEM+2 % horse serum for 3-7 days.  
3.2.3.2 Freezing and thawing of cells 
For long time storage about 106 cells were centrifuged at 200 x g, the cell pellet was resuspended 
in 1 ml FCS+10 % DMSO, cooled down in an isopropanol filled box to −80°C and latter 
transfered to liquid N2.  For thawing, the cells were warmed up quickly at 37°C and were seeded 
out into a 10 cm cell culture dish.  
3.2.3.3 Transfection 
3.2.3.3.1 Stable transfection 
In order to transfect the constitutively active form of AMPKα1 into mammalian cells, C2C12 
myoblasts were transfected with purified pTRE2-Hyg-AMPKα1-CA vector. To analyze, which 
transfection method is suitable to reach high transfection efficiency using C2C12 cells, three 
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different transfection approaches were applied: Metafectene, ExGen or calcium phosphate-based 
transfections were performed.  
 
Metafectene  
15-15 µg plasmid DNA was transfected with 30-30 µl Metafectene into cells seeded on two 10 
cm dishes according to the manual of the manufacturer.  
ExGen  
8 µg plasmid DNA was transfected with 53 µl ExGen into cells seeded on a 10 cm dish 
according to the manual of the manufacturer.  
Calcium phosphate 
Cells were transferred to 6 % CO2 for 30 minutes before and after transfection. 30 µg pTRE2-
Hyg-AMPKα1-CA plasmid DNA was mixed with 24 µg pRSETA in 1 ml 0.22 M CaCl2 
solution. They were incubated for 20 minutes and then mixed in small amounts with 1 ml 2x 
HBS. The calcium phosphate-DNA solution was incubated for 20 minutes, vortexed well and 2 
ml solution was given to two 10 cm dishes (1 ml solution/10 cm dish). Next day the calcium 
phosphate precipitate was discarded by washing the cells three times with PBS. 
2x HBS (Hepes-buffered saline)  280 mM NaCl 
10 mM KCl 
1.5 mM Na2HPO4
12 mM α-D-glucose 
50 mM HEPES 
pH 7.05 
3.2.3.3.2 Transient transfection 
Plasmid DNA transfection 
In order to perform reporter gene assays myoblasts were transfected at the stage of 30-50 % 
confluency. Usually 2-3 x 104 cells were seeded per one well of a 12-well plate one day before 
transfection. Metafectene was used as transfection reagent and was applied according to the 
manual of the manufacturer. Briefly, plasmid DNAs were mixed with OptiMEM and 
Metafectene was separately mixed with OptiMEM. Then the two solutions were combined and 
incubated at room temperature for 20 minutes. 100 or 200 µl plasmid DNA−Metafectene 
complex in OptiMEM was given to a well of a 12-well plate or a well of a 6-well plate. 0.5-1 µg 
DNA was transfected in a 1:3.33 ratio with Metafectene or in a 1:5 ratio with Lipofectamine 
2000 per one well of a 12-well plate. Non-confluent myoblasts were analyzed 24 hours, 
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confluent myoblasts 48-72 hours after transfection, myotubes were analyzed 96-144 hours after 
transfection. 
siRNA transfection 
In order to knock-down the mRNA of CREB-1 siRNA against the CREB-1 mRNA was 
transfected with Lipofectamine 2000 into 30-50 % confluency C2F3 cells. 9x 104 cells were 
seeded per one well of a 6-well plate one day before transfection. 5-100 nM siRNA was 
transfected with 4-15 µl Lipofectamine 2000 per well of a 6-well plate. Medium was changed 6-
24 hours after transfection. 
siRNA and plasmid DNA cotransfection 
In order to analyze the effect of CREB-1 acting on the cytochrome c promoter pGL3-cytochrome 
c-Firefly+pRL-CMV and siRNA SMARTpool against CREB-1 (NM 133828) or the appropiate 
siCONTROL siRNAs were cotransfected into 30-50 % confluency C2F3 cells. Usually 2-3 x 104 
cells were seeded per one well of a 12-well plate one day before transfection. 0.3 µg plasmid 
DNAs were cotransfected with 5 nM, 20 nM, 50 nM, 100 nM siRNAs and 1 µl, 1 µl, 2.5 µl and 
5 µl Lipofectamine 2000 per well, respectively. Promoter activity was analyzed 24 hours after 
transfection.  
3.2.4 Nucleic acids 
3.2.4.1 Total RNA preparation from C2F3 cells 
C2F3 myoblasts were seeded on 10 cm dishes and cultivated to 70-80 % confluency (non-
confluent myoblasts), to 100 % confluency (confluent myoblasts) or after myotube formation 
had been induced by a change to differentiation medium. Cells were harvested with trypsine, 
centrifuged (at 200 x g for 5 min at 4°C) and washed two times with ice cold PBS. After the last 
washing step the pellet was lysed in Trizol for 5 minutes. 0.2 ml chloroform was added, and the 
mixture was shaken vigorously for 15 seconds followed by a three minutes incubation. The tubes 
were centrifuged at 12,000 x g for 15 minutes at 4°C. The mixtures were separated to a lower red 
phenol-chloroform phase (proteins, DNA), an interphase (DNA) and a colourless upper aqueous 
phase (RNA). The RNA (aqueous) phase was transferred into a fresh tube and precipitated 
overnight by addition of 0.5 ml isopropanol at −80°C. The tubes were centrifuged at 12,000 x g 
at 4°C for 10 minutes, the supernatants were removed and the pellets were washed first with 
100 % ethanol (centrifuged at 7,500 x g for 5 minutes at 4°C) and then two times with 75 % 
ethanol. Then the pellets were air-dried for 20 minutes at room temperature and resuspended in 
15-30 µl RNAse-free DEPC-water. The RNA concentration was measured at 260 nm and 1 µg 
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RNA was loaded onto a 1 % agarose gel to check the integrity of the RNAs (without RNAse) 
stained with ethidium bromide.  
3.2.4.2 PolyA+ mRNA preparation from C2F3 cells 
C2F3 myoblasts were seeded on 10 cm dishes and cultivated to 70-80 % confluency (non-
confluent myoblasts) or to 100 % confluency (confluent myoblasts) or after at 100 % confluency 
myotube formation was induced by a change to differentiation medium (myotubes). Cells were 
harvested with trypsine, centrifuged (at 200 x g for 5 min at 4°C) and washed two times with ice 
cold PBS. After the last washing step the pellet was lysed in 1250 µl Lysis/Binding buffer and 
the protocol was continued according to the instructions of the Invitrogen Direct mRNA isolation 
kit. Briefly, the polyA-mRNAs were bound to Oligo(dT) Dynabeads, collected with a Dynal 
MPC-S magnetic bar, the unspecifically bound nucleic acids were washed off and the polyA-
mRNAs bound to the beads were eluted in 40 µl RNA loading buffer (see 3.2.4.4). Usually 20 µl 
from the eluate was used for Northern blot analysis.  
3.2.4.3 Random primed labeling of DNA 
The mouse CREB DNA sequence from 418 till 962 basepairs was amplified by PCR to generate 
a CREB probe (see 3.2.5.2). The PCR product was purified with PCR purification kit to discard 
the primer dimers and eluted in 30 µl 10 mM Tris (pH 8.0). 50 ng double stranded DNA was 
denatured by boiling at 100°C for 5 minutes. 40 µCi αP32-dCTP was used for the labeling by 
Klenow fragment with Random Primed DNA-Labeling Kit. The reaction was incubated for one 
hour at 37°C and the unincorporated αP32-dCTP was discarded by Chroma spin columns. The 
eluted radioactive probe was boiled at 100°C for 5 minutes and after a short centrifugation it was 
placed to ice before adding it to the hybridisation buffer. 
3.2.4.4 Northern Blot  
10 µg total RNA or 20 µl of polyA-mRNA samples in RNA loading buffer (without RNA 
loading dye) were heated to 65°C for 15 minutes, spin centrifuged, directly put on ice and 
completed with the RNA loading dye. Then they were loaded onto a 1.2 % denaturing agarose 
gel (with 1x MOPS buffer+ 6.5 % formaldehyd) and electrophoretically separated at 80 V for 5-
6 hours untill the bromphenol blue was migrated 10.5 cm from the top of the gel. The RNA was 
capillary transfered overnight in 10x SSC to a Gene Screen Plus Hybridization transfer nylon 
membrane and was crosslinked with 0.12 J/cm2 UV-light (wavelength 254 nm) for 1 min. The 
membrane was prehybridised at 50°C overnight in dextran sulfate hybridisation buffer then 
hybridised with the radioactively labelled mouse CREB probe in hybridisation buffer at 50°C for 
24 hours. The unspecifically bound, radioactively labelled probe was washed away with low 
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stringency buffer (usually two times for 7 minutes) and optionally with high stringency buffer 
(one to two times for 7 minutes). Fuji medical X-ray film (Super RX) was used to detect the 
specific mRNA signals and was usually exposed at −80°C for 24-48 hours.  
10x formaldehyde RNA loading dye   1 mM EDTA, pH 8.0 
       0.25 % bromphenol blue 
       0.25 % xylene cyanol 
       50 % glycerol 
RNA loading buffer     10 µg total RNA in 4.5 µl RNAse free water 
       1x MOPS 
       6.5 % formaldehyde 
       50 % formamide 
       2x RNA loading dye 
10x MOPS      0.4 M MOPS 
0.1 M sodium acetate 
0.01 M EDTA pH 8.0 
dextran sulfate hybridisation buffer    10 % dextran sulfate  
       1 M NaCl 
       1 % SDS 
low stringency buffer     2x SSC  
0.1 % SDS 
high stringency buffer    0.1x SSC  
0.1 % SDS 
20x SSC      3 M NaCl 
       0.3 M sodium citrate 
RNAse free water     0.1 % DEPC in distilled water 
3.2.5 Polymerase chain reaction (PCR) 
3.2.5.1 Reverse transcription 
In order to produce a probe against the gene of mouse CREB-1 and analyze the presence of 
CREB-1 isoforms total RNA was isolated from C2F3 cells (according to 3.2.4.1). Reverse 
transcription was made from 1 µg total RNA of myoblasts, confluent cells and myotubes using 
QuantiTect Reverse Transcription Kit according to the manual of the manufacturer (20 µl final 
volume).  
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3.2.5.2 PCR 
2 µl of the cDNA samples of growing myoblasts, confluent myoblasts and myotubes were used 
as a template in the CREB isoform specific PCR reaction with mCREB-103-5´ and mCREB-
396-3´ primers. 2 µl cDNA sample of growing myoblasts was used in CREB probe PCR reaction 
with mCREB 418 5´ and mCREB 962 3´ primers. 10 µl of PCR reactions were run on a 2 % 
agarose gel to visualize the PCR products. 
Usual PCR reaction 
2 µl cDNA 
1.5 mM MgCl2 
0.25 mM dNTP 
1 µM primer 1 and 2 
1x PCR buffer without MgCl2 
2.5-5 U Taq-Polymerase 
 
CREB isoform specific PCR 
92°C  2 min 
92°C  30 sec 
 
66°C  1 min 
72°C  1 min 
72°C  10 min 
4°C  ∞ 
CREB probe PCR 
92°C  2 min 
92°C  30 sec 
57°C  1 min   
3.2.6 Protein 
3.2.6.1 Preparation of
Trypsinesed cells were 
minutes. The cell pellet 
ice with frequent vortexi
and then thawed on ice 
centrifuged down at 15
solubilized proteins) wa
Protein Assay according
Totex buffer  20
   40
   2030x72°C  1 min 
72°C  10 min 
4°C  ∞ 
 whole cell extracts 
washed two times in PBS and centrifuged at 2
was resupended in about 2 volumens of Totex buf
ng for 10 minutes. The samples were incubated at 
with frequent vortexing for 10 minutes. The unso
,000 x g at 4°C for 10 minutes and the supern
s stored at –20°C. The protein concentration was 
 to Bradford [82]  standardized to 0-10 µg/ml BSA
 mM Hepes pH 7.9 
0 mM NaCl 
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00 x g at 4°C for 5 
fer, and incubated on 
–80°C for 20 minutes 
lubilized fraction was 
atant (containing the 
determined by Biorad 
 solution. 
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   1 % NP-40 
   1 mM MgCl2 
   0.5 mM EDTA 
   0.1 mM EGTA 
   10 mM β-glycerophosphat 
   10 mM NaF 
   5 mM DTT 
   0.5 mM Na3VO4  
   1 mM PMSF 
3.2.6.2 Nuclear and cytoplasmatic protein preparation 
Cells were washed with ice cold PBS, scraped in PBS+phosphatase inhibitors and centrifuged at 
200 x g at 4°C for 10 minutes. The pellet was resuspended in 1 ml hypotonic buffer (HB) and 
centrifuged at 200 x g at 4°C for 5 minutes. The pellet was resuspended in 200 µl HB+0.2 % NP-
40 buffer, and centrifuged at 17,700 x g at 4°C for 30 seconds. The supernatant was considered 
the cytoplasmatic fraction and the pellet was considered the nuclear fraction. The cytoplasmatic 
fraction was stored at –80°C and the nuclear fraction was resuspended in 20-100 µl HB+20 % 
glycerol buffer. The same volume (20-100 µl) HB+20 % glycerol+0.8 M NaCl buffer was added, 
the samples were incubated at 4°C for 30 min with constant mixing on a rotating wheel and 
centrifuged at 17,700 x g at 4°C for 10 minutes. The supernatant (nuclear extract) was aliquoted 
and stored at –80°C. Protein concentration was determined by Biorad Protein Assay according to 
Bradford [82]. 
PBS+phosphatase inhibitors  1 mM Na3VO4
5 mM NaF  
10 mM nitrophenylphosphate 
10 mM β-glycerophosphate 
in PBS 
Hypotonic buffer (HB)  20 mM Hepes (pH 7.9) 
1 mM Na3VO4
5 mM NaF 
10 mM nitrophenylphosphate 
10 mM β-glycerophosphate 
1 mM Na2MO4
0.1 mM EDTA 
1x protease inhibitors cocktail (Boehringer/Roche) 
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Hypotonic buffer+0.2 % NP-40 
Hypotonic buffer+20 % glycerol 
Hypotonic buffer+20 % glycerol+0.8 M NaCl 
3.2.6.3 Protein gel electrophoresis 
Denaturing SDS polyacrylamide gel electrophoresis (SDS-PAGE) was done according to 
Lämmli [83]. A 4 % SDS stacking gel and a 12.5 % SDS separation gel were cast in a Hoefer 
Tall Mighty Small SDS-PAGE chamber. Each sample was boiled for 5 minutes in 6x SDS 
loading dye before loading. Per lane, 6-8 µg nuclear protein or 30 µg total protein was loaded. 
The size of separated proteins was estimated using the PageRuler Prestained Protein Ladder. The 
gel was run in running buffer at 10-15 mA with constant current for 3-4 hours. 
stacking gel    0.1 % SDS 
     125 mM Tris pH 6.8 
    4 % acrylamide/bisacrylamide (29:1) 
    0.1 % APS 
    0.01 % TEMED 
separation gel    0.1 % SDS 
     375 mM Tris pH 8.8 
    12.5 % acrylamide/bisacrylamide (29:1) 
    0.1 % APS 
     0.01 % TEMED 
10x running buffer   250 mM Tris 
2 M glycine 
1 % SDS 
6x SDS protein loading dye  125 mM Tris pH 6.8 
     3 mM EDTA 
     20 % glycerol 
     9 % SDS 
     0.05 % bromphenolblue 
     10 % β-mercaptoethanol 
3.2.6.4 Western Blot 
After the run, the separation gel was transferred to an Optitran BA-S 85 reinforced nitrocellulose 
membrane (Whatmann) in western blot transfer buffer by 12.5 V for two and a half hour in a 
Hoefer transfer chamber. To ensure equal protein loading, Ponceau S staining was done. The 
membrane was saturated in blocking buffer for 1 hour, probed with the first antibody in blocking 
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buffer for 1 hour (at room temperature) or overnight (at 4°C). The membrane was washed in 
TBST three times for 10 minutes, then probed with the secondary antibody conjugated with 
horseradish peroxidase (HRP) in blocking buffer at room temperature for 1-2 hours and washed 
in TBST five times for 10 minutes. An Enhanced chemiluminescence (ECL) detection kit was 
used to visualize the horseradish peroxidase conjugated secondary antibody-first antibody 
complex and light emission was captured on Fuji medical X-ray film (Super RX) by 
autoradiography. To reprobe a membrane it was stripped in stripping buffer at 50°C for 30 
minutes. Then it was washed 5 times in TBST and blocked again in blocking buffer for 1 hour 
followed by probing with the new first antibody. 
transfer buffer    25 mM Tris 
0.2 M glycine 
0.1% SDS 
20 % methanol 
10x TBST    20 mM Tris pH 7.5 
     150 mM NaCl 
0.5 % Tween-20 
blocking buffer   5 % (w/v) non-fat milk powder 
     1x TBST 
stripping buffer   50 mM Tris pH 6.8 
     2 % SDS 
     0.1 M β-mercaptoethanol 
3.2.6.5 Immunoprecipitation 
In order to determine the kinase activity of endogenous AMPKα1 or the AMPKα1-CA, the 
kinase was immunoprecipitated with a specific antibody. The cells were washed two times with 
PBS and dried in air. 0.75 ml lysis buffer was added (per 10 cm dish) and incubated at 4°C for 
30 min with constant mixing on a rotating wheel. The cells were scraped and centrifuged at 
13,000 x g at 4°C for 20 min. The supernatant was put into a new 1.5 ml tube and protein 
concentration was measured according to Bradford. 200 µg of protein was taken and the volume 
was adjusted to 1 ml with lysis buffer. In the preclearing step, 10 µl Protein A-G-beads were 
given to the lysate and incubated at 4°C for 1 hour with constant mixing on a rotating wheel. The 
samples were centrifuged at 610 x g for 5 minutes and the supernatant was transferred into a new 
1.5 ml tube. AMPKα1-CA was immunoprecipitated by 10 µg anti-c-myc antibody, the 
endogenous AMPKα was immunoprecipitated by 1:100 anti-AMPKα antibody (Cell Signaling) 
or by 1:50 anti-AMPKα antibody (gift from Dr. Carling) at 4°C for 1 hour with constant mixing 
                                                                                                                       Materials and Methods 
 36
on a rotating wheel. 40 µl Protein A-G-beads were added to the samples and incubated at 4°C 
overnight with constant mixing on a rotating wheel. The immunoprecipitated proteins were 
pelleted by centrifugation at 610 x g at 4°C for 1 minute. The supernatant was kept for western 
blot. The pelleted complex was washed two times with buffer A and two times with buffer B. 
One half of the beads was mixed with 6x SDS loading dye for Western blotting, the other half 
was analyzed in the kinase assay. 
Lysis buffer (Buffer A)  50 mM Tris pH 7.5 
1 mM EDTA 
1 mM DTT 
10 % glycerol 
50 mM NaF 
5 mM sodium pyrophosphate 
1 mM benzamidine 
0.1 mM PMSF 
1 % Triton-X 100 
Buffer B    50 mM Tris pH 7.5 
1 mM EDTA 
10 % glycerol 
1 mM DTT 
3.2.6.6 Kinase assay 
In order to measure the kinase activity of endogenous AMPKα1 or the AMPKα1-CA, kinase 
assay was performed. The AMPK kinase bound beads were resuspended in 30 µl kinase buffer 
and incubated at 30°C for 30 minutes. The reaction was stopped by centrifugation at 9,000 x g 
for 30 seconds and the supernatant was transferred into a new 1.5 ml tube. 15 µl supernatant was 
applied onto a phosphocellulose P81 Whatman cation exchange paper. It was washed with 1 % 
H3PO4 three times for 20 minutes each, then it was finally washed with acetone and dried in air. 
The immunoprecipitated AMPK enzyme phosphorylates the SAMS peptide 
(HMRSAMSGLHLVKRR), so the SAMS peptide labelled with radioactive phosphate was 
measured with scintillation counting. 
Kinase buffer    40 mM Na-Hepes pH 7.0 
0.2 mM AMP  
80 mM NaCl  
0.8 mM DTT  
5 mM MgCl2  
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10 % glycerol  
0.2 mM SAMS peptide  
0.18 mM ATP (cold)+0.02 mM 2 µCi 32P γATP (hot) 
3.2.6.7 Phosphatase treatment of nitrocellulose membrane 
In order to analyze the phosphorylation status of the CREB-1 double bands SDS-PAGE was 
performed and the proteins were transferred to Optitran BA-S 85 reinforced nitrocellulose 
membrane (Whatman). The membrane was blocked in blocking buffer for one hour and then 
incubated in phosphatase buffer with constant mixing on a rotating platform at 4°C overnight. 
The membrane was washed with PBS-0.1 % Tween 20 for 5 minutes, then with TBST three 
times for 10 minutes each. Afterwards the normal western blot protocol was followed with the 
first antibody probing and etc. 
Phosphatase buffer   1 % BSA 
     0.1 % Triton X-100 
     2 mM MnCl2
     5 mM DTT 
     1200 U/ml lambda-phosphatase 
     in TBS 
3.2.7 Reporter gene assay 
The promoter activities were determined by luciferase reporter gene assay with two expression 
vectors. pRL-CMV vector consists of a constitutively active cytomegalovirus promoter (CMV) 
upstream of the renilla luciferase gene of the sea pansy Renilla reniformis. The second plasmid 
with the promoter of interest had the cytochrome c pro moter fragment to be analyzed upstream 
of the firefly luciferase gene of the firefly Photinus pyralis. The plasmids were transfected into 
logarithmically growing (12-well plate seeded) myoblasts with Metafectene or with 
Lipofectamine 2000. Usually 3-6 parallel samples were used. Non-confluent myoblasts were 
analyzed 24 hours after transfection, confluent myoblasts 48-72 hours after transfection, 
myotubes were analyzed 96-144 hours after transfection. The cells were washed with PBS and 
lysed in 200 µl Passive lysis buffer per well. After 5 minutes incubation the cells were collected 
and centrifuged at 20,000 x g at 4°C for 10 minutes. The supernatant was transferred in a new 
tube and a 50 µl aliquot was used in 400 µl firefly buffer+100 µl injected firefly substrate buffer. 
A second 50 µl aliquot was used in 400 µl renilla buffer+100 µl injected renilla substrate buffer. 
Light emission was detected with a Sirius luminometer for 10 seconds. The values from 
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transfected cells were corrected with the values of untransfected cells and each firefly value was 
normalized to its renilla value according to the following equation: 
Renilla  tonormalized lueFirefly va
cells) cted(untransfeRLUcells) ed(transfectRLU
cells) cted(untransfeRLUcells) ed(transfectRLU
RenillaRenilla
FireflyFirefly
=−
−
 
 
Firefly buffer    25 mM glycine-glycine pH 7.8 
     1 mM DTT 
     15 mM KH2PO4 
15 mM MgSO4 
   4 mM EGTA 
Firefly substrate buffer  25 mM glycine-glycine pH 7.8 
     15 mM MgSO4 
     4 mM EGTA 
     2 mM DTT 
     0.2 mM D-Luciferine 
Renilla buffer    0.5 M NaCl 
     0.1 M KH2PO4 
     1 mM EDTA 
     0.02 % BSA 
     0.6 mM NaN3 
     pH 7.6 
Renilla substrate buffer  renilla buffer+0.2 µM coelenterazine 
3.2.8 Microscopy 
3.2.8.1 Indirect immunofluorescence 
C2C12 cells were grown on a 4 cm cell culture dish and differentiated to myotubes with horse 
serum for 4-7 days. Cells were washed twice with PBS and fixed with methanol at −80°C for 10 
minutes. Then the cells were washed twice with PBS and twice with PBS-0.2 % gelatine. Mouse 
monoclonal 1F11 anti-MHC antibody was used in a dilution of 1:2 at 37°C for 45 minutes. The 
cells were washed twice with PBS, two times with PBS-0.2% gelatine and fluorescein-
conjugated antibody raised against mouse IgG was added in 1:50 dilution at 37°C for 30 
minutes. The cells were washed twice with PBS, twice with PBS-0.2% gelatine and the nuclei 
were stained with 1 µg/ml Hoechst 33258 diluted in PBS. After two final washing steps with 
PBS, the treated area of the dish was quickly dried and covered with 10 µl Mowiol buffer and a 
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cover slip. The fluorescein labelled antibody was visualized with a Zeiss Axiophot 
immunofluorescence microscope and fusion index was determined with the help of Perfect 
Image software according to the following equation: Fusion index [%]=(nuclei in myotubes/total 
nuclei) x 100. Four independent areas were analyzed and an average of them was calculated. 
Mowiol buffer  2.4 g Mowiol 4-88 
6 g glycerol 
    6 ml H2O 
    12 ml 0.2 M Tris pH 8.5 
    2.5 % 1,4-diazobicyclo-(2.2.2)-octane DABCO 
3.2.8.2 Intracellular calcium measurement 
To determine the intracellular calcium concentration of cells, they were raised on cover slips. 
Before the measurement, the culture medium was aspirated and the cells were washed two times 
with PSS buffer, then loaded with PSS buffer containing 5 µM Fura-2 AM usually for 30-60 
minutes. All measurements and the incubation steps were performed at 37°C. To reduce the 
background, Fura-2 AM was removed before the measurement by washing the cells with PSS 
buffer. Dual wavelength measurements of Fura-2 AM fluorescence were performed using a setup 
based on a Zeiss microscope equipped with a PLAN Neofluar 16x objective. Emission 
wavelength of 510 nm and excitation wavelength of 340 nm/380 nm were achieved with a 
multiway wavelength illumination system (POLYCHROME II). Spatiotemporal Ca2+ 
distributions were determined using a CCD-camera with 100 ms exposure time and 2 fold 
binning. Acquisition and analysis of the fluorescence images was done by TillVision (v4.01) 
software. All signals were background corrected and the ratio of the excitation at 340 nm/380nm 
was used for analysis. 
PSS buffer   118 mM NaCl  
5 mM KCl  
1.6 mM CaCl2  
1.2 mM MgCl2
24 mM HEPES 
10 mM glucose 
pH 7.4 
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3.2.9 Statistical analysis 
Calculating the significance between the samples two-tailed, Student´s t-test was performed with 
unpaired, unequal distribution and p value was illustrated to be significant, when the value was 
less than or equal with 0.5. 
3.2.10 Software tools 
AIDA 2.1  
TillVision v4.01 
Perfect Image 
                                                                                                                                                Results 
4 Results 
4.1 In vitro model for muscle differentiation and mitochondrial 
biogenesis 
The mouse skeletal muscle cell lines C2C12 and C2F3 retain their potency to differentiate 
from mononucleated, growing myoblasts in a “muscle progenitor” stage through a stage of 
confluent, quiescent myoblasts to multinucleated myotubes in an end-differentiated stage [80]. 
We chose this model to study mitochondrial biogenesis because the cells are easy to maintain 
and differentiate and the amount of mitochondria increases during differentiation [2,3].  
 
 
Figure 6. C2F3 cells during differentiation  
Growing myoblasts were split every two to three days, but were not allowed to reach confluence since this 
decreases the differentiation capacity. For differentiation, cells were seeded at 50-80 % confluence. After 
reaching 100% confluence, growth medium was changed to differentiation medium containing 2 % horse 
serum and the cells were kept for additional three to five days. The differentiation level increased with time 
and reached a stationery phase after three to five days. Myotubes were distinguishable from myoblasts under 
the light microscope, as they were larger and had several nuclei. 
4.1.1 Expression of differentiation markers during myogenesis 
Since it is not possible to induce a state of 100 % differentiation, every myotube culture 
contains myoblasts as well. To quantify differentiation, we calculated the fusion index, the ratio 
of nuclei in myotubes vs. all nuclei by double staining for a differentiation marker (MHC) and 
nuclei, respectively (Figure 7).  
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Figure 7. MHC expression of differentiated C2C12 myotubes  
After cell fixation the differentiation marker myosin heavy chain (MHC) was stained with an anti-myosin 
heavy chain antibody (red) while the nuclei were visualized with Hoechst 33258 staining (blue). The right 
panel shows the overlay of the two staining. The numbers illustrate the calculated fusion indices of the 
representative areas at the right side.  
 
The number of nuclei in MHC positive myotubes were divided by the total number of nuclei, 
resulting in the fusion index. Usually the fusion index was between 40-78 %.  
During muscle differentiation several other proteins like myogenin, MyoD, myf5 and 
MRF-4 are also upregulated [84]. Western blot analysis was performed from nuclear extracts of 
C2F3 cells to visualize the myogenin protein, which is a good marker for the activated muscle 
differentiation program. Figure 8 shows that myogenin is not present in growing myoblasts, but 
appears in confluent myoblasts and remains in myotubes. MHC and myogenin expression 
indicate that by fusion, the muscle differentiation program of C2C12 and C2F3 muscle cells is 
indeed executed. 
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Figure 8. Myogenin expression in differentiating C2F3 cells  
Nuclear extracts were prepared from four parallel samples of myoblasts, confluent cells and myotubes and 
were probed by Western blot with antibodies against myogenin or β-actin, which was used as a loading 
control. 
 
4.1.2 Intracellular calcium levels in myoblasts and myotubes 
As a second messenger, calcium is involved in several physiological pathways and plays 
an important role in the muscle differentiation process [19]. The elevation of intracellular 
calcium by the ionophore A23187 was shown to moderately induce transcription of cytochrome 
c and its promoter activity [85] as well as the phosphorylation level of AMPK [22]. Furthermore 
CaMKIV, which is one of the protein kinases phosphorylating and thus activating CREB-1 and 
which is also known to be involved in the mediation of mitochondrial proliferation [86], 
upregulates the expression of mitochondrial enzymes upon increased intracellular calcium 
concentrations [21]. Thus, we addressed the question whether resting intracellular calcium 
concentration differs between myoblasts and myotubes. Calcium levels were measured by 
staining with a fluorescent calcium binding dye, Fura-2 and it was found that the 340/380 ratio, 
reflecting the calcium concentration, was significantly higher in myoblasts compared to 
myotubes (Figure 9). 
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Figure 9. Calcium concentration in C2C12 cells during the differentiation process 
Intracellular calcium concentration was determined by fluorescence measurement of the calcium indicator 
Fura-2 and the 340/380 ratios are illustrated on the y axis. C2C12 myoblasts and myotubes were loaded for 60 
minutes with Fura-2 followed by a 5-10 minutes post incubation. Data are mean ± standard deviation obtained 
from three independent experiments. ** indicates a significant difference (p<0.01) between myoblasts and 
myotubes. 
 
However, time course experiments showed that Fura-2 uptake was higher in myotubes 
compared to myoblasts (data not shown). Thus, to exclude artifacts according to an unequal 
concentration of Fura-2 in myoblasts vs. myotubes, fluorescence was determined every 10 
minutes during the loading period and five minutes after the loading. We observed a solid 
increase in the 340 or 380 nm mean fluorescence values during loading reflecting the rising level 
of Fura-2 in the cytosol (Figure 10A), but the ratio of 340/380 increased only moderately with 
the loading time (Figure 10B). In every time point, myotubes picked up more Fura-2 than 
myoblasts, but the ratio of 340/380 of myotubes was always smaller or similar to myoblasts 
during the whole loading process (Figure 10). 
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Figure 10. Calcium concentration of C2C12 cells during the loading procedure 
Intracellular calcium concentration was determined by fluorescence measurement of the calcium indicator 
Fura-2. C2C12 myoblasts (blue) and myotubes (orange and red color) were loaded from 10 to 60 minutes with 
Fura-2 followed by a five minutes post incubation period. Data are mean ± standard deviation obtained from 
three myoblast and four myotube samples. A the individual fluorescence intensities at 340 nm, 380 nm as well 
as B the ratios of 340/380 are illustrated on the y axis. ** indicates a significant difference (p<0.01), *** 
indicates a significant difference (p<0.001) between myoblasts and myotubes. Unless it is not indicated there 
were no significant differences between myoblasts and myotubes. 
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Since differentiation and probably mitochondrial biogenesis is initiated at the step of confluence, 
we measured calcium level in the confluent stage, in which cells were incubated either with 
differentiation medium containing horse serum or cultivated in fetal calf serum. It was suggested, 
that 100 % confluence is needed to execute the muscle differentiation program, while horse 
serum alone is not sufficient to induce differentiation. To study how cell density influences 
resting calcium, cells were seeded at low to high densities. The calcium concentration was 
significantly increased in confluent cells seeded at high cell density (95 %) in the presence of 
horse serum compared to cells cultivated at the same densities in fetal calf serum (Figure 11, 
right columns). However, cells seeded at low densities (30 and 60 %) did not show elevated 
calcium concentration upon change to horse serum (Figure 11, first four columns). Surprisingly, 
the fluorescence intensity of Fura-2 at 340 nm was enhanced about to two-three fold by horse 
serum, independent of the starting cell concentration (Figure 11, white columns). In conclusion, 
intracellular calcium levels were found to be higher in myoblasts compared to myotubes, while 
differentiation medium alone seems to increase calcium concentration in confluent cells, 
suggesting that calcium elevation occurs after the confluent stage during muscle differentiation. 
 
 
Figure 11. Calcium concentration in confluent C2C12 cells 
Intracellular calcium concentration was determined by fluorescence measurement of the calcium indicator 
Fura-2. The individual fluorescence intensities at 340 nm or the 340/380 ratios are illustrated on the y axis. 
Cells were seeded at 30, 60, 95 % cell densities two days before the experiment and cultivated in FCS. Cells 
were then cultivated with (+HS) or without horse serum (−HS) for additional 16 hours. Confluent myoblasts 
were loaded with Fura-2 for 1 hour followed by a 15 minutes post incubation period. Data are mean ± standard 
deviation obtained from five samples. *** indicates a significant difference (p<0.001) of 340 nm fluorescence 
values in the presence or absence of HS. ## indicates a significant difference (p<0.01) of 340/380 ratios in the 
presence or absence of HS. Unless it is not indicated there were no significant differences of 340/380 ratios in 
the presence or absence of HS. 
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4.1.3 α-actinin4 localization during differentiation 
Goffart et al. have recently identified a new palindromic sequence, which was found to be 
common in a large number of nuclear encoded mitochondrial genes. Proteins binding to this 
sequence were identified by preparative EMSA and MALDI/TOF. One of these cis-element 
binding proteins, α-actinin4, was shown to have an altered binding pattern in EMSA when 
myoblasts were compared to myotubes [87]. Thus, Western blot analysis from nuclear and 
cytoplasmic extracts of myoblasts and myotubes were performed to verify possible altered 
expression of α-actinin4. The levels of α-actinin4 in the cytoplasmic fraction of myoblasts, 
confluent cells and myotubes were equal (Figure 12A and C). However, compared to myoblasts 
the nuclei of myotubes and confluent cells showed a significant, two- to threefold higher content 
of α-actinin4 (Figure 12B and D). In both cellular fractions, two different proteins, β-actin and 
β-tubulin for cytoplasmic fractions and β-actin and histone H1 for nuclear fractions, respectively 
were used as loading controls. The expression levels of these loading controls correlated well 
with each other. The purity of nuclei was confirmed by additional Western blot analysis. β-actin 
is expressed about equally in cytoplasmic and nuclear fractions, histone H1 was only observed in 
the nuclei and as expected β-tubulin was found mainly in the cytoplasmic fractions (Figure 12E). 
The α-actinin4 nuclear translocation occurring during myogenesis indicates that it is a possible 
transcription factor, which binds the newly identified cis-element and may transactivate muscle 
specific genes. 
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Figure 12. Expression of α-actinin4 in nuclear and cytoplasmic fractions of C2F3 cells 
Western blots of A cytoplasmic and B nuclear fractions were prepared from myoblasts, confluent cells or 
myotubes and probed with antibodies as indicated. The intensity of bands was evaluated densitometrically for 
C cytoplasmatic and D nuclear fractions. Data are mean ± standard deviation obtained from four samples 
normalized to the loading controls. * indicates a significant difference (p<0.05), ** indicates a significant 
difference (p<0.01) of the α-actinin4/histone H1 ratio between myoblast values and confluent cells/myotube 
values. ## indicates a significant difference (p<0.01) of the α-actinin4/β-actin ratio between myoblast and 
myotube values. E Nuclear (N) and cytoplasmic proteins (C) were analyzed by Western blot side-by-side to 
control the purity of the nuclear fraction. 
 
 
 
 48
                                                                                                                                                Results 
 49
4.2 The role of AMPK in cytochrome c promoter regulation 
4.2.1 Cloning of AMPKα1-CA into pTRE2Hyg vector  
The truncation of the full-length AMPKα1 protein at position 312 creates an AMPK 
lacking the interaction domain with β and γ subunit, but preserves the kinase domain. This 
constitutively active AMPKα1-CA was successfully used in former studies [40,41,88] to 
investigate the effect of the kinase without the need of phosphorylation by the upstream kinase. 
The pcDNA3-AMPKα1-CA construct contains the sequence of the rat AMPKα1-CA 
downstream of a viral, constitutively active promoter. Our initial aim was to create a muscle cell 
line expressing AMPKα1-CA protein in an inducible manner. Therefore, we chose the 
Tetracycline (Tet) regulated system, in which the expression of the gene of interest is activated 
by the TRE (Tetracycline response element) promoter in the presence of the transactivator 
protein producing helper vector. In the presence of Tetracycline or its derivatives Doxycycline 
(Dox), the transactivator protein binds the ligand resulting in the inhibition of transcription (Tet-
Off system).  
In order to express the AMPKα1-CA in mammalian cells, its cDNA sequence was cloned 
from pcDNA3-AMPKα1-CA into the mammalian expression vector pTRE2Hyg. 
4.2.2 Generation of stable cell lines expressing tTA transactivator  
C2C12 E6 and C2C12 D3 clones were provided by Prof. Brüning (Köln), stably expressing 
the transactivator from the inserted plasmid pCMV-tTA and were tested for their Dox sensitivity 
using a pTRE2Hyg-Firefly reporter plasmid, which was transiently transfected to test the 
inducibility (Figure 13). Both clones expressed the Firefly protein, but D3 gave a higher absolute 
luciferase activity. In both cases the transcription from the TRE promoter was blocked in the 
presence of Dox, and 1 µg/ml was enough for at least a 5-fold decrease. However, an enzyme 
activity still remained with even 5 µg/ml Dox suggesting that the system is leaky. In the 
following experiments the C2C12 D3 clone was used and transfected with the pTRE2Hyg-
AMPKα1-CA plasmid to generate stable clones. 
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Figure 13. TRE promoter activity in TRE transactivator (tTA) expressing cells 
Firefly luciferase activity was measured in (A) C2C12 E6 or in (B) C2C12 D3 cells driven by the TRE 
promoter in the presence or absence of Dox. Data are mean ± standard deviation obtained from six samples. 
RLU: relative light units 
 
 C2C12 E6 and D3 cell lines were also tested for the optimal amount of Hygromycin B, the 
selection antibiotic to eliminate those cells, which did not take the plasmid. 100, 300, 500, 700, 
900 µg/ml Hygromycin B concentrations were given to the cell culture medium and the cell 
viability was monitored for five days. 700 µg/ml was enough to kill all the cells in five days, 
therefore this concentration was used in further experiments. 
4.2.3 Transfection, isolation and selection of AMPKα1-CA clones 
The C2C12 D3 cells were transfected with the pTRE2Hyg-AMPKα1-CA construct. The 
selection was started after two days in the presence of G418 (Neomycin) and Hygromycin B. 
Dox was also included in the medium to inhibit the expression of AMPKα1-CA. Growing clones 
were isolated after two weeks and transferred to separate wells. From 300 isolated clones 71 
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were further cultivated to a high scale. AMPKα1-CA expression was induced by removal of Dox 
for two days, total protein was extracted and the samples were tested for the expression of 
AMPKα1-CA by Western blot analysis. 
4.2.4 Analysis of AMPKα1-CA clones 
The AMPKα1-CA contains an N-terminal c-myc tag, which was used to detect the 
AMPKα1-CA expression in the transfected cells. Purified Myc-tagged coronin 7 protein was 
used as positive control while C2C12 D3 untransfected cells served as negative control (Figure 
14). The AMPKα1-CA protein has a predicted molecular weight of 37 kDa, but unfortunately in 
this range an artificial background band also appeared, which was present in the negative control 
D3 cells as well.  
 
 
Figure 14. AMPKα1-CA clones using anti-c-myc antibody 
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Western blot analysis of AMPKα1-CA expressing C2C12 D3 clones in the presence (+) or absence (−) of 
Dox. C2C12 D3 cells were used as negative control, purified coronin-7 Myc-fusion protein as positive control. 
The size of molecular weight markers is given in kDa. 
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To exclude this artifact we changed our strategy and used an AMPKα specific antibody instead 
of anti-c-myc antibody, which recognizes the endogenous wild-type AMPKα subunits (white 
arrow, molecular weight 63 kDa) but also well detects the truncated AMPKα1-CA protein (black 
arrow) at 37 kDa (Figure 15 and Appendix Figure 2).  
 
 
Figure 15. Western blot of AMPKα1-CA clones using anti-AMPKα antibody (showed 
partially) 
Western blot analysis of AMPKα1-CA expressing C2C12 D3 clones in the presence (+) or absence (−) of 
Dox. C2C12 D3 cells were used as negative control. White arrow shows the endogenous and black arrow the 
AMPKα1-CA proteins. The complete screening of AMPKα1-CA clones illustrated in the Appendix Figure 2. 
The size of molecular weight markers is given in kDa. 
 
Table 2 summarizes the results: From 71 clones 68 were analyzed and 49 were found to be 
positive for AMPKα1-CA expression, but none of them were Dox regulated, as AMPKα1-CA 
was produced also in the presence of Dox. Some clones seemed to be regulated by Dox, but this 
was not reproducible in further experiments. Clone 27 was chosen as strong expressor, clone 5 as 
intermediate and clone 1 as no expressor to analyze the effect of the constitutively active 
AMPKα1 subunit in latter experiments.  
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Table 2. Summary of the AMPKα1-CA clones1
 
Name* Exp.#  Name Exp.  Name Exp.  Name Exp.  Name Exp. 
CA-1 -  CA-16 +  CA-31 -  CA-46 +  CA-61 + 
CA-2    CA-17 +  CA-32 -  CA-47 +  CA-62 - 
CA-3 -  CA-18 +  CA-33 +  CA-48    CA-63 + 
CA-4 +  CA-19 +  CA-34 +  CA-49 +  CA-64 + 
CA-5 +  CA-20 +  CA-35 +  CA-50    CA-65 - 
CA-6 -  CA-21 -  CA-36 -  CA-51 +  CA-66 + 
CA-7 -  CA-22 +  CA-37 +  CA-52 +  CA-67 + 
CA-8 +  CA-23 +  CA-38 +  CA-53 +  CA-68 + 
CA-9 +  CA-24 +  CA-39 -  CA-54 +  CA-69 + 
CA-10 -  CA-25 +  CA-40 +  CA-55 +  CA-70 + 
CA-11 -  CA-26 +  CA-41 +  CA-56 +  CA-71 + 
CA-12 -  CA-27 +++  CA-42 +  CA-57 -    
CA-13 +  CA-28 +  CA-43 +  CA-58 +    
CA-14 +  CA-29 -  CA-44 +  CA-59 +    
CA-15 -  CA-30 -  CA-45 +  CA-60 -    
 
1 The table summarizes the results of Western blot analysis from Figure 15 and Appendix Figure 2 illustrating  
the induction level of AMPKα1-CA. 
* indicates the name of the AMPKα1-CA clones, 
# illustrates the expression (+) or the lack (-) of AMPKα1-CA protein from whole cell extracts, 
+++ indicates strong AMPKα1-CA expression. 
 
4.2.5 Immunoprecipitation of AMPKα1-CA 
In order to study whether the AMPKα1-CA expressing cell line has an increased kinase 
activity, kinase assays were performed. The AMPKα1-CA protein was immunoprecipitated from 
an extract of the strong expressor CA-27 clone. To test the efficiency of the commercial antibody 
in immunoprecipitation experiments, different amounts were used and proteins bound to the 
beads were detected with the same AMPKα antibody. As depicted in Figure 16A, the AMPKα 
antibody could not completely deplete the expressed AMPKα1-CA protein from the supernatant 
of CA-27. Therefore, AMPKα1-CA protein was immunoprecipitated with a c-myc antibody. 
Figure 16B shows that 10 µg c-myc antibody was enough to completely precipitate the 
AMPKα1-CA protein from the cell lysate, as no protein was visible after immunoprecipitation in 
the supernatant. The beads specifically bound the AMPKα1-CA protein expressed by clone 27, 
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while beads incubated with extracts from clone 1, which does not express the fusion protein, 
showed no specific protein binding. Strong immunoreactivity is present in the molecular range of 
AMPKα1-CA, but a distinct AMPKα1-CA band is detected in the beads sample of clone 27, 
while it is missing from the beads sample of clone 1 (Figure 16B, rectangles). 
 
 
Figure 16. Immunoprecipitation of AMPKα1-CA by AMPKα or c-myc antibodies  
Western blot was probed with commercial AMPKα antibody. A Samples were prepared from AMPKα1-CA-
27 (strong expressor) cell lysate with 0.1, 1 or 5 µg AMPKα antibody (Cell Signaling) B The samples were 
prepared from AMPKα1-CA-27 and CA-1 (non expressing) cell lysates with 10 µg c-myc antibody. Lysate: 
cell lysate before immunoprecipitation, Supernatant: cell lysate after immunoprecipitation, Beads: proteins 
eluted from the beads after immunoprecipitation 
 
4.2.6 AMPKα1 and AMPKα1-CA kinase assay 
The kinase activity of AMPKα1-CA was determined from clone 27, clone 1 and C2C12 
D3 untransfected cells. The strong expressor cell line clone 27 showed an elevated AMPKα1-
CA kinase activity compared to the non-expressing clone 1 and the untransfected control (Figure 
17A). The presence of Dox did not influence the kinase activity in agreement with its inability to 
inhibit the expression of AMPKα1-CA. To compare the constitutively active to the endogenous 
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AMPKα1 activity, the endogenous kinase was immunoprecipitated with a commercial anti-
AMPKα antibody. Interestingly, no or very low kinase activity was obtained (Figure 17B), 
which could be a consequence of incomplete immunoprecipitation (Figure 16A). Thus, to study 
the endogenous AMPKα1 kinase activity an antibody provided by Dr. Carling was used to 
immunoprecipitate the endogenous AMPKα1 (Figure 17B). The basal kinase activity was found 
to be similar in myoblasts, confluent cells and myotubes (Figure 17C). However, the endogenous 
kinase activity was about eight times higher as the highest AMPKα1-CA kinase activity (Figure 
17A and C).  
In conclusion, we established a cell line expressing the AMPKα1-CA continuously, which 
has an elevated kinase activity. However, comparing AMPKα1-CA to the endogenous kinase 
activity there is an eight times difference between them. 
 
Figure 17. Endogenous AMPKα1 and AMPKα1-CA kinase assays  
A Kinase activity of the anti-c-myc Ab immunoprecipitated AMPKα1-CA from myoblasts of C2C12 D3 and 
AMPKα1-CA-1 (negative control) and CA-27 (strong expressor) cell lines in the presence (+) or absence (−) 
of Dox. B Endogenous AMPKα1 activity immunoprecipitated by Cell Signaling anti-AMPKα or anti-
AMPKα1 Ab provided by Dr. Carling. C Endogenous AMPKα1 activity immunoprecipitated by anti-
AMPKα1 Ab provided Dr. Carling from C2C12 myoblasts, confluent cells and myotubes. Data are from a 
single experiment. cpm: counts per minutes 
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4.2.7 Analysis of cytochrome c promoter activity in AMPKα1-CA 
expressing cells 
To investigate whether the constitutively active AMPKα1 activates the cytochrome c 
promoter we transfected stable AMPKα1-CA clones with a cytochrome c reporter gene construct 
containing the full length rat cytochrome c promoter upstream a firefly reporter gene and with a 
control CMV promoter-activated renilla reporter gene. The cell lysate used for luciferase 
measurement was also tested by Western blot to check the expression level of AMPKα1-CA. 
These results confirmed the former experiments, namely clone 1 used as negative control does 
not express the AMPKα1-CA, clone 5 expresses it in a moderate level and clone 27 is a strong 
expressor of the fusion protein (Figure 18).  
 
 
Figure 18. AMPKα1-CA protein expression level in AMPKα1-CA clones 
Western blot probed with anti-AMPKα Ab (Cell Signaling) was performed from the lysate of C2C12 D3, 
clone 1, clone 5 and clone 27 cell lines used for luciferase assays. All cells were maintained in the absence of 
Dox. White arrow shows the endogenous AMPKα and the black arrow the AMPKα1-CA proteins. 
 
Despite of the expression of AMPKα1-CA the cytochrome c promoter activity was neither 
elevated in the intermediate expressor clone 5 nor in the strong expressor clone 27 (Figure 19A). 
Confirming earlier experiments, Dox did not change the expression of AMPKα1-CA (Figure 18) 
hence it did not have any effect on the cytochrome c promoter activity (Figure 19A). The 
approach to transiently overexpress the AMPKα1-CA efficiently enough was not successful (Dr. 
Carling, personal communication). In order to come to the conclusion, we finally transiently 
cotransfected two dominant negative constructs, dominant negative AMPKα1 and α2, together 
with cytochrome c firefly and renilla reporter vectors. Cytochrome c promoter activity was 
determined in myoblasts, confluent cells and in myotubes. Overexpression of AMPK dominant 
negative constructs did not change the cytochrome c promoter activity, neither in myoblasts nor 
in confluent cells nor in myotubes (Figure 19B). However, the activity of cytochrome c promoter 
was increased several fold upon differentiation comparing myoblasts to myotubes, verifying the 
induction of the promoter upon myogenesis, previously shown [32]. 
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Figure 19. Cytochrome c promoter activity in (A) AMPKα1-CA stablely transfected cell 
lines or (B) transiently transfected cells  
A The promoter activity was measured in C2C12 D3 untransfected myoblasts or in stable myoblasts of clone 
1, 5, 27 in the presence (+) or absence (−) of Dox. B The promoter activity was measured in the presence of 
pcDNA3 empty vector, AMPKα1-DN or AMPKα2-DN (dominant negative) vectors in myoblasts, confluent 
cells or myotubes. Data are mean ± standard deviation obtained from (A) six or (B) nine samples. 
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4.3 CREB-1 is involved in cytochrome c promoter regulation 
 Former experiments of the laboratory suggested that CREB-1 is necessary for the 
activation of the cytochrome c promoter during muscle differentiation (see 2.3 and [32]).  
4.3.1 CREB-1 and ATF-1 during myogenesis 
 The expression pattern of CREB-1 isoforms was investigated in C2F3 myoblasts, confluent 
cells and myotubes. The total amount of CREB-1 proteins decreased during the differentiation 
program (Figure 20A and B) but the level of phosphorylated CREB-1 level remained unchanged 
(Figure 20C and D). Surprisingly, both the anti-CREB and anti-P133-CREB antibody, which 
recognizes Ser-133 phosphorylated CREB-1 proteins, detected two CREB-1 immunoreactive 
bands (Figure 20A and C) with an almost similar molecular weight (42 and 43 kDa). We called 
them CREB-1α and CREB-1∆ (see below), being the possible products arising from two 
different alternatively spliced isoforms of the CREB-1 gene product. The anti-CREB antibody 
also recognizes the ATF-1 protein with about 37 kDa molecular weight. The amount of ATF-1 
decreased during the differentiation as well (Figure 20A and G), while the P-ATF-1 level was 
highest in myoblasts, significantly decreased in confluent cells and increased again in myotubes 
(Figure 20C and H). One should note that for visualizing ATF-1 expression, the Western blot 
had to be exposed for much longer time periods, than for detecting CREB-1. However, this 
longer exposure time does not mean a lower ATF-1 level in these cells, as the antibody is only 
72 % homologous to the ATF-1 protein sequence in contrast to the 100 % homology to the 
CREB-1 protein. Ratios were calculated from the intensity of the upper (CREB-1α) and the 
lower CREB immunoreactive band (CREB-1∆). The CREB-1α/CREB-1∆ ratio increased about 
threefold during myogenesis (Figure 20A and E), while the P133-CREB-1α/P133-CREB-1∆ 
ratio was elevated significantly about eightfold in myotubes compared to myoblasts (Figure 20C 
and F).  
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Figure 20. Protein expression of CREB-1 family members during muscle differentiation 
Nuclear extracts were made from myoblasts, confluent cells and myotubes. A CREB-1 and ATF-1, or C P133-
CREB-1 and P-ATF-1 proteins were detected with the antibodies indicated on the left side of the picture. 
Histone H1 level was used as internal loading control and values were normalized to it. The total B CREB-1, 
D P133-CREB-1 or G ATF-1 level were densitometrically evaluated as well as the E CREB-1α/CREB-1∆, F 
P133-CREB-1α/P133-CREB-1∆ ratios or H P-ATF-1 protein amounts. Data are mean ± standard deviation 
obtained from three samples. * indicates a significant difference (p<0.05), ** indicates a significant difference 
(p<0.01), *** indicates a significant difference (p<0.001) between myoblast values and confluent/myotube 
values. Unless it is not indicated there were no significant differences between myoblast values and 
confluent/myotube values. 
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4.3.2 CREB-1 isoforms in C2F3 cells 
Western blots showing double CREB-1 immunoreactive bands initially led us to the first 
hypothesis that they are phosphorylated and unphosphorylated forms of CREB-1. By incubation 
with phosphatase, both phospho-133 CREB immunoreactive bands however disappeared, while 
the intensity of the CREB-1 immunoreactive bands remained unchanged (Figure 21), indicating 
that both bands are phosphorylated. 
 
  
Figure 21. Phosphatase treatment of CREB-1 immunoreactive bands  
Nuclear extracts of confluent cells were separated with SDS-PAGE and blotted to a nitrocellulose membrane. 
The membrane was treated with (+) or without (−) phosphatase followed by antibody probing, as indicated 
above the picture. 
 
Thus, alternatively, these double bands could be the CREB-1 family members CREB-1 and 
CREM. To investigate this, specific CREB-1 recognizing antibodies were used in nuclear 
extracts of C2F3 cells. The anti-CREB antibody from Cell Signaling recognizes every CREB-1 
family member: CREB-1, CREM and ATF-1, while the antibody from Upstate recognizes only 
CREB-1, but not CREM and ATF-1. A specific antibody was used from Santa Cruz directed 
against the exon 5 domain, which is present in CREB-1α but spliced out from the mRNA of 
CREB-1∆.  
The results showed that Cell Signaling and Upstate antibodies recognize the same double 
bands (Figure 22), which exclude the presence of the CREM protein. The Santa Cruz antibody 
detects only a single immunoreactive band with the same molecular weight as the upper band 
detected by Cell Signaling and Upstate antibodies. These Western blots thus indicate that these 
bands are the CREB-1α (upper band) and CREB-1∆ (lower band) isoforms present in C2F3 cell 
nuclei. 
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Figure 22. Identification of CREB-1α and CREB-1∆ protein isoforms by Western blot 
Nuclear extracts of confluent cells were probed with antibodies recognizing every CREB-1 family member 
(Cell Signaling), only the CREB-1 isoforms (Upstate) or exclusively the CREB-1α isoform. 
 
To further support the existence of CREB-1 isoforms generated by alternative splicing, 
semiquantitative RT-PCR reverse transcription was performed from mRNA of C2F3 cells. The 
primer pairs used for the PCR reaction were chosen to be specific for the two isoforms. PCR 
products for both isoforms were detected in myoblasts, confluent cells and myotubes as well 
(Figure 23A). Samples were taken from 22 to 36 cycles to determine the logarithmic phase of the 
PCR reaction for semiquantitative measurements. At 30 cycles the reaction was not in the 
exponential phase anymore, while 27 cycles were found to be still in the log phase (Figure 23A 
and B).  
 
 
Figure 23. Determining the log phase for semiquantitative RT-PCR 
A Reverse transcription was performed from mRNA of myoblasts (B), confluent cells (C) and myotubes (T). 
CREB-1 PCR, using primers specific for both isoforms was performed from 22 to 36 cycles. B 
Densitometrical evaluation of the intensity of CREB-1α and CREB-1∆ PCR products.  
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27 cycles were used to amplify cDNA samples of myoblasts, confluent cells and myotubes. 
However, no difference was found in the intensity of the CREB-1α and CREB-1∆ PCR products 
during muscle differentiation (Figure 24).  
 
 
Figure 24. Distribution of CREB-1α and CREB-1∆ mRNA isoforms during myogenesis 
A Reverse transcription was performed from mRNA of myoblasts, confluent cells and myotubes and CREB-1 
PCR using primers specific for both isoforms was performed for 27 cycles. B Densitometrical evaluation of 
the intensity of CREB-1∆/CREB-1α PCR products. Data are mean ± standard deviation obtained from three 
samples. There were no significant differences between myoblast values and confluent/myotube values. 
 
To further analyze the transcription products of the CREB-1 gene, Northern blot analysis 
was performed from mRNA samples of C2F3 cells (Figure 25). However, in contrast to previous 
NCBI database information, the mRNA of mouse CREB-1α is 8431 nucleotides, of CREB-1∆ is 
8389 nucleotides long according to most recent data. Since, the only difference between the two 
sequences is the 42 bp exon 5 coding 14 amino acid, it was impossible to separate the 8.4 and 8.3 
kb sequences from each other with Northern blot technique. In these muscle cells, beside CREB-
1α and ∆, CREB-1β was also present at mRNA level and further experiments suggested that the 
double bands showed by Figure 23 and 24 correspond to CREB-1α and ∆ (data not shown). 
 
 62
                                                                                                                                                Results 
 
Figure 25. CREB-1 gene expression detected by Northern hybridization 
PolyA-mRNA was prepared from myoblasts, confluent cells and myotubes and hybridized to a probe against a 
mouse CREB-1 sequence, which is common in both isoforms. At the left, sizes of RNA molecular weight 
marker are given in bp. 
 
4.3.3 Knock-down of CREB-1 by siRNA technology 
In order to further analyze whether CREB-1 regulates the cytochrome c promoter, we 
wanted to specifically inhibit its expression by siRNA directed against the mRNA of CREB-1. 
Four different siRNA sequences were used in a pool and they were able to decrease the protein 
level after one to three days. The highest knock-down effect was reached 24 hours after 
transfection, thus this time point was used in latter experiments (Figure 26A and B). However, 
the negative pool siRNA used as a negative control also inhibited CREB-1 protein expression, 
although the difference was not as strong as in the case of CREB-1 siRNA (Figure 26A and B). 
To exclude such off-target effects caused by high amounts (100 nM) of siRNA, in the next 
experiment 25-100 nM siRNA were tested. However, each concentration of negative controls 
(negative #1 and negative pool) interacted with the endogenous CREB-1 protein expression, and 
even in the presence of the transfection reagent Lipofectamine 2000 alone, a similar effect was 
detected (Figure 26C and D).  
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Figure 26. siRNA against CREB-1 decreases CREB-1 protein 
A C2F3 cells were transfected with 100 nM negative pool (neg.) control siRNA or with 100 nM siRNA against 
CREB-1 for 1-3 days, nuclei were extracted and CREB-1 protein amount was checked by Western blot. B 
Densitometrical evaluation of the intensity of the CREB-1 protein bands normalized to β-actin given in % of 
untransfected control. C 25-100 nM negative #1 or negative pool siRNA were used as siRNA control and 25-
100 nM siRNA against CREB-1 was transfected to knock-down CREB-1 protein expression. The nucleus 
preparation was performed 24 hours after transfection and CREB-1 protein amount was checked by Western 
blot. D Densitometrical evaluation of the intensity of the CREB-1 protein bands normalized to β-actin given in 
% of untransfected control. C: untransfected control, L: Lipofectamine 2000 alone. 
 
This means that the transfection procedure itself unspecifically counteracted with the 
endogenous CREB-1 protein expression, although the specific siRNA decreased CREB-1 
expression according to the siRNA concentration (25 nM, 50 nM, 100 nM siRNA caused 74 %, 
82 %, 85 % knock-down of CREB-1 protein level, respectively) (Figure 26C and D). 
 Nevertheless, we cotransfected the CREB-1 siRNA with a cytochrome c reporter construct 
to see whether knock-down of CREB-1 could interact with the promoter activity. Different 
concentration of siRNA against CREB-1 decreased the cytochrome c promoter activity as did the 
negative control #1 or negative pool control (Figure 27). This experiment and the Western blots 
showed again that the transfection itself could cause an unspecific off-target effect counteracting 
with the CREB-1 protein expression and/or with the cytochrome c promoter activity. Thus, the 
siRNA approach was not suitable to answer the question whether CREB-1 interacts with the 
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cytochrome c promoter. Therefore, to solve this problem we changed our strategy using a 
constitutively active and dominant negative form of CREB-1, respectively. 
 
 
Figure 27. Cytochrome c promoter activity upon siRNA cotransfections 
5-100 nM control siRNA (negative #1 and negative pool) or 5-100 nM siRNA against CREB-1 were 
cotransfected with cytochrome c promoter-firefly and renilla reporter vectors. The cytochrome c promoter 
activity was measured 24 hours after transfections, normalized to renilla values and given in % of 
untransfected control. Data are mean ± standard deviation obtained from three samples.  
 
4.3.4 The effect of CREB-1 constructs on the cytochrome c promoter 
C2/CREB is a constitutively active form of CREB-1, which contains the activation domain 
of CREB-2 fused to the basic DNA binding/Leucine zipper dimerization domain (bZIP) of 
CREB-1 and acts as a CREB-1 transcriptional activator, independently of the phosphorylation 
state. It was cotransfected with cytochrome c promoter-firefly and renilla reporter vectors in the 
presence or absence of a dominant negative CREB construct called A-CREB (plasmids were 
kind gifts of Prof. Thiel, Homburg). A-CREB consists of only the basic DNA binding/Leucine 
zipper dimerization domain (bZIP) but lacks the N-terminal activation domain. Therefore it 
serves as a specific repressor by dimerizating with the endogenous CREB-1 and thus forming an 
inactive CREB-1/A-CREB dimer. The α-inhibin promoter was used as a positive control as it 
contains well-described CRE sequences [88]. Cytochrome c and α-inhibin promoters were 
upregulated four and twelve times, respectively in confluent cells compared to myoblasts (Figure 
28A and B). The C2/CREB construct significantly activates the cytochrome c and α-inhibin 
promoters in myoblasts as well as in confluent cells (Figure 28A and B). Cotransfecting the 
dominant negative A-CREB significantly diminished the C2/CREB overactivated promoter 
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activity, in myoblasts and also in confluent cells (Figure 28A and B). This suggests that CREB-1 
directly regulates the cytochrome c promoter. 
 
 
Figure 28. Cytochrome c and α-inhibin promoter activities modulated by CREB-1 
Cytochrome c or α-inhibin promoters were cotransfected with renilla control and with C2/CREB constitutively 
active (light grey column) or with pCMV empty (dark grey column) or with A-CREB dominant negative 
vector (black column). A Cytochrome c or B α-inhibin promoter activities were measured from myoblasts or 
confluent cells and normalized to the basal promoter activities of myoblasts. Data are mean ± standard 
deviation obtained from 12 samples and normalized to the transfected cells lacking the C2/CREB plasmid. # 
indicates a significant difference (p<0.05), ### indicates a significant difference (p<0.001) in the presence or 
absence of C2/CREB construct (white and light grey columns). * indicates a significant difference (p<0.05), 
*** indicates a significant difference (p<0.001) between C2/CREB construct alone (light grey column) and 
C2/CREB+pCMV (dark grey column) or C2/CREB construct alone (light grey column) and C2/CREB+A-
CREB constructs (black column). Unless it is not indicated there were no significant differences among the 
samples. 
 
4.3.5 Modulating the activity of PKA and PP2 phosphatases 
Since Ser-133 phosphorylation of CREB-1 is necessary for its transcriptional activity, we 
finally addressed the question, which kinase(s) or phosphatases modulate its phosphorylation in 
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muscle cells. The activity of protein kinase A (PKA) and PP2 phosphatases were blocked or 
activated by a specific activator or inhibitors, respectively. PP2A phosphatase was blocked with 
okadaic acid, while PP2B (calcineurin) was inhibited by Cyclosporin A. PKA was activated with 
a specific activator called Sp-5,6-DCI-cBIMPS and inhibited with the inhibitor Rp-8-CPT-
cAMPS. The toxicity of the applied chemicals was monitored for 4-5 days (data not shown) and 
concentrations, which were not toxic, were used in the latter experiments. The phosphorylation 
of CREB-1 was analyzed by Western blot with the phosphoserine-133 specific antibody in C2F3 
myoblasts. Okadaic acid and Cyclosporin A phosphatase inhibitors increased the 
phosphorylation of CREB-1 (Figure 29A, B and 30A, B). Sp-5,6-DCI-cBIMPS activated and 
Rp-8-CPT-cAMPS blocked the phosphorylation of CREB-1 as they are supposed to activate or 
inhibit the activity of PKA, respectively (Figure 29C, D and 30C, D). However, 5 nM Okadaic 
acid seemed to modify the cell shape of differentiated C2F3 myotubes, since in contrast to long 
myotubes in untreated or with 50 pM or 500 pM Okadaic acid treated wells, round myotubes 
appeared on the 5 nM Okadaic acid treated wells (data not shown). 
 
 
Figure 29. PKA and PP2 phosphatases influences the phosphorylation status of CREB-1 
Myoblasts were treated for 24 hours in the presence of phosphatase and PKA inhibitors or PKA activator. 
Western blots of isolated cell nuclei were probed with P133-CREB antibody and representative pictures are 
shown. A PP2A was inhibited with Okadaic acid B PP2B (calcineurin) with Cyclosporin A, C PKA was 
activated with Sp-5,6-DCI-cBIMPS D and inhibited with Rp-8-CPT-cAMPS with the given concentrations. 
Cells were treated with DMSO as negative control.  
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Figure 30. Quantitation of phospho133-CREB-1 intensities upon treatment with 
phosphatase and PKA inhibitor or PKA activator  
Myoblasts were treated for 24 hours in the presence of phosphatase and PKA inhibitors or PKA activator. 
Western blots of isolated cell nuclei were probed with P133-CREB antibody and evaluated densitometrically, 
normalized to β-actin and given as the % of untransfected control. Cells were treated with DMSO as negative 
control. A PP2A was inhibited with Okadaic acid B PP2B (calcineurin) with Cyclosporin A, C PKA was 
activated with Sp-5,6-DCI-cBIMPS D and inhibited with Rp-8-CPT-cAMPS with the given concentrations. A-
B data are mean ± standard error obtained from 2-3 independent experiments C-D data are mean ± standard 
deviation obtained from 2-3 samples. * indicates a significant difference (p<0.05), *** indicates a significant 
difference (p<0.001) between chemical treated and untreated samples. Unless it is not indicated there were no 
significant differences among the samples. 
 
 These activator and inhibitors were also included in cytochrome c promoter assays to 
evaluate whether alterations of Ser-133 phosphorylation of CREB-1 could change the activity of 
the promoter. Only Cyclosporin A increased moderately the cytochrome c promoter activity in 
C2F3 myoblasts, while other chemicals did not interact with our model promoter (Figure 31A). 
In differentiated myotubes none of the chemicals were able to change the cytochrome c promoter 
driven luciferase activity (Figure 31B). In summary, Cyclosporin A increased the Ser-133 
phosphorylation of CREB-1 as well as the cytochrome c promoter activity suggesting a possible 
role of PP2B (calcineurin) regulating the function of CREB-1 in muscle cells. 
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Figure 31. Cytochrome c promoter activity in the presence of phosphatase and PKA 
inhibitors or PKA activator 
Cells were treated for A 24 or B 120 hours with the indicated kinase or phosphatase inhibitors or activator. 
PP2A was inhibited with Okadaic acid, PP2B (calcineurin) with Cyclosporin A and PKA was activated with 
Sp-5,6-DCI-cBIMPS and inhibited with Rp-8-CPT-cAMPS with the given concentrations. Cytochrome c 
promoter activity was determined A in myoblasts or B in differentiated myotubes. Data are mean ± standard 
deviation obtained from three samples. * indicates a significant difference (p<0.05) between untreated control 
and 2 µM Cyclosporin A treated cells. 
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5 Discussion 
Mitochondrial biogenesis is a well controlled and complex process. The pathways 
responsible for transmitting the signals for an increased amount of mitochondria are not well 
understood. To investigate candidates involved in this process, regulation of cytochrome c 
promoter during skeletal muscle differentiation was used as a representative model. Specifically, 
we asked the question whether the AMP activated kinase (AMPK) or the cyclic AMP-response 
element binding protein 1 (CREB-1) are responsible for regulating mitochondrial biogenesis in 
this situation.  
5.1 Comparison of undifferentiated and differentiated muscle cells 
5.1.1 Enhanced myogenic marker gene expression in differentiating muscle 
cells 
C2F3 or C2C12 mouse skeletal muscle cell lines were used to study mitochondrial 
biogenesis upon muscle differentiation in vitro. During this process, the mitochondrial amount as 
well as mitochondrial enzyme activities are elevated comparing multinucleated myotubes with 
precursor myoblasts [2]. The differentiation program of skeletal muscle is mediated by the 
family of myogenic regulatory factor (MRFs) proteins. The primary MRFs, MyoD and Myf-5 
determine the cell faith, while the secondary MRFs, myogenin and MRF-4 induce myoblasts to 
fuse with each other to myotubes. MRFs heterodimerize through their basic helix-loop-helix 
domain (bHLH) with other bHLH transcription factors and bind the E-box cis-element of muscle 
specific gene promoters [89]. Myosin heavy chain (MHC) can be also used to determine the 
differentiation state of muscle cells, as its expression can be detected first at the time of myoblast 
fusion and remains high in muscle fibers, but is missing in growing myoblasts [90].  
Skeletal muscle cell lines were induced to differentiate by fusion of growing myoblasts to 
quiescent myotubes. Myogenin was detected by Western blot in confluent cells and myotubes 
but not in growing subconfluent C2F3 myoblasts (Figure 8). In parallel, MHC protein was 
exclusively expressed in differentiated C2C12 myotubes investigated by indirect 
immunofluorescence, showing that these cells were successfully differentiated.  
5.1.2 Altered intracellular calcium levels during differentiation 
 Calcium is an intracellular messenger involved in many cellular functions. In muscle cells 
after membrane depolarization calcium channels open in the sarcoplasmatic reticulum (SR) and 
the increase of intracellular calcium concentration is a prerequisite for actin-myosin interaction. 
Furthermore, calcium activates several calcium dependent protein kinases and phosphatases and 
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is essential for the ordered sequence of muscle differentiation. It has been shown that cell 
commitment, phenotypic differentiation as well as cell fusion need an increase of the 
intracellular calcium concentration [91]. In the presence of EGTA, an extracellular calcium 
chelator, myoblast differentiation was diminished, while the calcium ionophor A23187 promotes 
muscle differentiation, increasing the number of fused myotubes [92]. Upon chelating the 
intracellular calcium with the membrane permeable BAPTA-AM, the number of differentiated 
myotubes detected by immunofluorescence was suppressed in a dose dependent manner. 
Additionally, BAPTA-AM not only decreased the resting calcium level of treated myoblasts, but 
also the activated calcium influx mediated by storage activated calcium channels [93]. L-type 
calcium channels were found to contribute to the elevation of the intracellular calcium level in 
cultivated muscle cells, and inhibiting this calcium channel with specific inhibitors decreased 
expression of myogenin and disturbed myoblast fusion. At the same time, suppressing the rise of 
intracellular calcium by inhibiting the sarcoplamatic reticulum calcium channels, also diminished 
the number of differentiated myoblasts [19]. In muscle cells NMDA glutamate receptors were 
also found to be responsible for the calcium influx upon muscle differentiation, since glutamate 
treatment elevated the number of fused myoblasts, while a specific NMDA inhibitor suppressed 
this effect [94]. Recent detailed analyses indicate that post-natal myoblasts can use three 
alternative mechanisms to elevate their intracellular calcium level: the release from internal 
stores, the influx through storage and through voltage operated channels [93]. Mitochondria are 
also involved in the maintenance of intracellular calcium level mediated by its Na+/Ca2+ 
exchanger and Ca2+ uniporters. Challet et al. indicated a ryanodine receptor (RyR) dependent 
oscillation in mitochondrial calcium, suggesting that mitochondria communicate very tightly 
with the SR in myotubes [95].  
The ratios of 340 and 380 nm fluorescence intensities suggest that myoblasts have 
significantly higher calcium concentrations compared to myotubes (Figure 9). Enhanced 
intracellular calcium is involved in muscle fiber type fast-to-slow twitch transformation [96], 
since chronic low-frequency stimulation (CLFS) of fast-twitch muscle fibers generates a long-
term, two to three-fold time higher calcium concentration as in unstimulated muscle fibers and 
cause massive upregulation of mitochondria in vivo [97]. Kubis et al. also reported an elevated 
calcium level upon electrostimulation of cultured cells, which in contrast with the repetitive 
peaks of short calcium transients seemed not to be involved in the activation of calcineurin-
NFATc1 pathway. This signal pathway contributes to the fast-to-slow fiber type transition in 
skeletal muscle cells via upregulating slow myosin heavy chain gene expression [24]. CLFS 
suppressed the SR Ca2+-ATPase activity [97] and it was suggested that decreased ATP levels 
may reduce the calcium flux into the SR producing an increased intracellular calcium 
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concentration. Indeed an elevated cytosolic calcium concentration was found in fibroblasts of 
MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) patients, 
harboring a point mutation of mtDNA in the gene coding for the mitochondrial leucine-tRNA. 
The fibroblasts of affected patients showed normal levels of ATP, but an impaired mitochondrial 
membrane potential, suggesting that not the mitochondrial ATP production rather than its 
calcium sequestering capacity may contribute to this increased calcium level [98]. Depleting 
mtDNA by ethidium bromide or poisoning the mitochondrial respiration with different inhibitors 
also invoke a higher resting calcium concentration in C2C12 cells. These interventions decreased 
the cellular ATP level and enhanced the ryanodine receptor 1 mRNA and protein levels, which is 
thought to play a role in the contraction triggered calcium influx [99]. Thus, calcium may be an 
important initial trigger for mitochondrial biogenesis and an insufficient ATP production by 
mitochondria may be a retrograde signal for transmitting the need for an increased mitochondrial 
mass. Indeed, initial differentiation by high confluence and serum withdrawal leads to a 
significant rise in intracellular calcium (Figure 11, 95 % starting cell density). This was not 
observed under suboptimal condition of cell confluence (Figure 11, 30 and 60 % starting cell 
densities).  
However, muscle differentiation is a slow, genetically determined process, hence the 
changes of activating pathways and the resulting biological answers happen during a different 
time scales. Several calcium activated processes invoke spatially and temporally distinct calcium 
waves such as single spikes, sustained low plateaus or repeating oscillations [99]. Our calcium 
imaging microscopic tool was not suitable to monitor intracellular calcium concentration over 
several days so an important calcium peak during initiation of differentiation may have been 
missed, which may crucial to trigger the following events.  
In conclusion, we observed that in the beginning of differentiation at the myoblast stage, 
C2C12 cells have an increased level of calcium when comparing them to the end-stage 
differentiated myotubes (Figure 9), and the intracellular calcium is elevated during the 
differentiation process upon serum withdrawal (Figure 11). Thus calcium may be important for 
muscle differentiation and therefore calcium activated phosphatases were studied later. 
5.1.3 α-actinin4 translocates to the nuclei of myotubes 
In our laboratory, a new sequence motif was detected, which was found in the promoter 
sequence of cytochrome c, TFAM, COXIV as well as many other nuclear encoded mitochondrial 
gene promoters. This sequence was shown by EMSA experiments to bind a protein complex and 
the abundance and binding affinity of these DNA binding proteins were different in myoblasts 
compared to myotubes. The complexes isolated from nuclear extracts of myotubes contained 
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several proteins and one of them was α-actinin4, identified by mass spectrometry. 
Immunofluorescence experiments showed that myoblasts contain α-actinin4 in a diffuse pattern 
but the protein is localized mainly in the nucleus in myotubes [87].  
Western blots verified the results of the immunofluorescence staining, since nuclear levels 
of α-actinin4 were enhanced two to three times in myotubes compared to myoblasts, although 
the cytoplasmic level of the protein remained unchanged (Figure 12). α-actinin4 is usually 
localized outside of the nucleus and it is thought to regulate the interaction of plasma membrane 
and cytoskeleton, since it is involved in several endo- and exocytosis processes [100,101]. 
However, in distinct cancer cell lines a nuclear localization of α-actinin4 was also shown [102] 
and in podocytes it is present at the plasma membrane, while in transformed kidney cells (HEK) 
it is found in the perinuclear cytosol [103]. Thus, the localization of this protein strongly depends 
on the cell type or physiological conditions. The presence of α-actinin4 in the nucleus suggests 
its possible involvement in transcription processes, and one of its isoforms, α-actinin2 was 
recently shown to function as a coactivator [104]. Thus  α-actinin4 could also be involved in 
DNA binding or may act as a coactivator in the formation of a transcriptional complex at the 
promoter of nuclear genes encoding mitochondrial proteins.  
5.2 Overexpression of AMPKα1-CA in C2C12 cells 
 To investigate whether AMPK mediates mitochondrial biogenesis in muscle cells, we 
chose the Tet-Off system, which is a method to suppress the expression of the gene of interest in 
the presence of Tet or Dox and to switch on its expression by withdrawal of the antibiotics. The 
cDNA of the constitutively active AMPKα1 was cloned into the vector pTRE and this construct 
was transfected into C2C12 D3 cells, which express the TRE transactivator. Clones were isolated 
and were analyzed by Western blot for expression of AMPKα1-CA. However, Dox did not 
regulate the levels of the AMPKα1-CA protein at all (Figure 15 and Appendix Figure 2). The D3 
transactivator expressing cell line had been tested for Dox suppression of the TRE promoter and 
a ten times decreased, but not silent promoter activity was obtained in the presence of 1 µg/ml 
Dox (Figure 13B). These results suggest that there are other factors, which impair in these cells 
the ability of Dox to inhibit the transactivator protein. Obviously, a low level of transcription was 
enough to produce similar amounts of AMPKα1-CA protein as in activated cells in the absence 
of Dox (Figure 15 and Appendix Figure 2). Other results of our laboratory confirm this 
phenomenon, since C2C12 E6 cells expressing EGFP driven by the TRE are also unable to 
inhibit its expression in the presence of Dox (Franko and Darvas, unpublished data). Indeed, 
Sommer et al. reported that the Tet-Off system was leaky in C2C12 cells, since they also 
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obtained transgene expression in the non-activated state [105]. To overcome this limitation, these 
authors generated an autoregulatory Tet-Off system, which provided higher induction factors 
with low basal expression in the non-induced state [106]. The Tet-Off system was recently 
compared with other inducible expression systems and the results indicate that this system 
although reaching the highest maximum expression level, is comparably leaky and has only a 
small induction capacity [107]. Personal communications with the company providing the 
vectors (Becton Dickinson) also indicated that this Tet-Off system is not universally suitable for 
every cell line. To confirm this, the TRE promoter containing a firefly luciferase reporter 
plasmid was transfected into C2F3 and C2C12 cells. Interestingly, we achieved a high amount of 
luciferase activity driven by the TRE promoter and Dox did not affect this expression (Figure 
32). This unwanted expression from the TRE promoter denotes that there are transcription 
factors in these cells, which could bind and induce the transcription from the TRE promoter even 
in the absence of the specific transactivator protein. An alternative explanation for this 
constitutive expression could be that the chromosomal environment triggers the activation of the 
transgene even in the presence of Dox due to the presence of activator or enhancer sequences. 
However, Dox was able to inhibit the expression of the transgene in C2C12 D3 cells, which have 
the TRE transactivator, but its suppressing capacity was lower as in previous experiments, 
compare Figure 32 and 13B. Altogether, cell lines were established, which constitutively express 
the AMPKα1-CA protein, but with no possibility of regulation.  
 
 
Figure 32. TRE promoter activity in muscle cell lines  
A TRE promoter driven firefly luciferase reporter plasmid was cotransfected with an SV-40 promoter driven 
renilla luciferase control vector into C2F2, C2C12 cells or C2C12 D3 (TRE transactivator expressing) cell 
lines. Luciferase activity was determined 24 hours after transfection in the presence (+) or absence (−) of 
doxycycline (Dox). The firefly luciferase values were normalized to renilla values and data are mean ± 
standard deviation obtained from 5 samples. 
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 The activity of AMPKα1-CA was confirmed by kinase assays, and accordingly Dox did 
not affect the kinase activity (Figure 17A). The endogenous AMPKα1 kinase activity was also 
determined and was found to be about nine times higher as the maximal activity of AMPKα1-
CA (Figure 17B). Calculating the phosphate amount incorporated into the SAMS peptide, 
AMPKα1-CA phosphorylated 1.8 pmol/min/mg phosphate, while the endogenous kinase 
phosphorylated 15.7 pmol/min/mg phosphate (calculated from the dark grey column of Figure 
17A and the light grey column of Figure 17B). The difference between the endogenous α1 and 
AMPKα1-CA kinase activity is in line with data obtained by Stein et al., who also found a much 
higher endogenous compared to the AMPKα1-CA activity obtained after transfection [40]. They 
suggested that due to the inability to bind the regulatory β and γ subunits, the truncated 
AMPKα1-CA may not localize normally and that this may explain the low kinase activity [40]. 
Only when using an adenoviral system, the AMPKα1-CA kinase activity was higher as the 
endogenous [108], meaning that a high transfection efficiency is also a prerequisite for an 
appropriately high activity. However, this does not fully explain the low kinase activity in stable 
clones, where every cell expresses the construct.  
Nevertheless, cytochrome c promoter expression was not different in clone 27 or clone 5, 
which express AMPKα1-CA at high or intermediate levels, respectively (Figure 18 and 19A). 
Also, in transient transfection experiments the cytochrome c promoter activity remained the 
same upon cotransfection of dominant negative forms of AMPKα1 or AMPKα2 proteins, 
confirming that AMPK does not regulate the cytochrome c promoter (Figure 19B). In addition, 
the endogenous kinase activity was measured but no difference was detected among myoblasts, 
confluent cells and myotubes (Figure 17C).  
In conclusion, we generated cell lines expressing AMPKα1-CA, which despite of its 
constitutive kinase activity was not able to alter the expression of the cytochrome c promoter, 
indicating that either AMPKα1 itself is not involved in this process or that the total AMPK 
activity we achieved was not high enough to trigger an appropriate answer.  
5.3 CREB-1 regulates the cytochrome c promoter 
Former studies of our laboratory and other results suggested that CREB-1 is important for 
regulating nuclear encoded mitochondrial genes [32] and a model of a CREB-1 transcriptosome 
was built according to these results (Figure 33). 
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Figure 33. A model for a transcriptosomal complex on mitochondrial genes 
The black line illustrates the DNA sequence of a model promoter with chosen cis-elements thought to play a 
role during the process of muscle differentiation. The grey circle represents the RNA II polymerase and the 
broken arrow shows the transcriptional start site. 
 
To investigate this hypothesis in more detail, the expression level of CREB-1 was analyzed 
by Western blot. We found a decrease in the overall CREB-1 amount without changing the 
overall Ser-133 phosphorylation status of the protein (Figure 20A-D). Thus, the overall Ser-133 
phosphorylated CREB-1 compared to the total CREB-1 protein is elevated upon muscle 
differentiation suggesting a role of phosphorylated CREB-1 in this process. The transcription 
factor ATF-1, which also belongs to the CREB-1 family, dropped during differentiation and 
phospho-ATF-1 levels reduced (Figure 20A, C, G and H) denoting that ATF-1 could be 
important in the first stage of muscle differentiation. Surprisingly, Western blot analysis showed 
that in the 42-43 kDa molecular weight range, two CREB-1 reactive bands were detected, which 
reacted with anti-CREB as well as with anti-Ser-133 phospho-CREB antibodies (Figure 20A and 
C). In further experiments we identified these double bands as the CREB-1α and CREB-1∆ 
products of the same gene generated probably by alternative splicing (Figure 21 and 22). The 
presence of the isoforms was also proven at the mRNA level and CREB-1∆ was found to be the 
predominant mRNA, and the ratio of CREB-1α and CREB-1∆ mRNA remained the same during 
the differentiation process (Figure 23 and 24). 
5.3.1 CREB-1 isoforms are present in different tissues 
Although the presence of CREB-1α and ∆ isoforms was discovered already in 1990, the 
function of them still remains obscure. Yamamoto et al. showed that in rat brain the predominant 
isoform is the CREB-1∆ on the mRNA as well as the protein level as well. They found that in 
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vitro, the capacity for transactivation of the rat CREB-1α isoform is approximately 10 times 
higher as CREB-1∆ [109]. However, another study indicated that the two human CREB-1 
isoforms bind to their DNA target with similar strength [110]. Also, the mouse CREB-1α and ∆ 
transcriptional activities were found to be equal, but the mRNA ratio showed, as in the former 
studies, that CREB-1∆ is the mainly expressed isoform [111]. The discrepancy of the α domain 
causing different transcriptional activity in vitro in the three species were explained by minor 
amino acid variations among them [111]. In addition to the α- and ∆-isoforms, other CREB-1 
isoforms were detected, namely CREB-1αγ, γ, Ω, Ψ. They differ by the presence or absence of 
further domains derived from alternatively spliced exons, but all originate from the same gene. 
All of them are truncated proteins lacking the bZIP domain, thus they have been suggested to 
rather function as repressors counteracting CREB-1α or ∆. Expression of CREB-1 γ and αγ was 
strongly induced upon spermatogenesis, indicating a role in this process [111]. Also, the nuclear 
localization signal of CREB-1∆ was determined to be at the amino acid positions 287-295, which 
is situated in the bZIP domain, suggesting a cytoplasmatic localization of all shorter isoforms 
lacking this domain [112]. Two other mouse CREB-1 isoforms were discovered latter and named 
CREB-1∆-14 and CREB-1∆-35, due to the absence of 14 nucleotides of exon 9 or 35 nucleotides 
of exon 8. Since they lack the bZIP domain, they were indeed localized in the cytosol but still 
had a capacity for blocking the transcriptional activity of CREB-1α in CRE reporter gene assays. 
As these isoforms are cytoplasmic and the full length CREB-1 is located in the nucleus, the 
hypothesized role for their action is that they act as pseudosubstrates of PKA and thereby 
decrease the phosphorylation of endogenous CREB-1. Both of them were shown to be widely 
expressed in several tissues but they were enriched in brain, thymus and testis [113]. 
Homologues of these CREB-1 isoforms were observed in Aplysia brain as well. While the full 
length CREB-1a serves as an activator of long term facilitation in this organism, CREB-1b is a 
repressor and CREB-1c is thought to be an activator of long term memory dependent on CREB-
1a [114].  
Disrupting the second exon of CREB-1 in mice caused a complete loss of CREB-1α and ∆ 
expression, but CREM, which belongs to the classical CREB-1 family and a new CREB-1 
isoform, called CREB-1β, were upregulated and compensated the loss of CREB-1α and ∆ in 
these animals [115,116]. In wild-type tissues CREB-1β and CREB-1α mRNA are expressed to 
about the same level, and both contribute to about 1/3, while CREB-1∆ is thought to contribute 
to about 2/3 of the overall CREB-1 mRNA pool. CREB-1β was able to transactivate CRE-
sequence containing model promoters, so it was considered to be a transcriptional activator as 
well [116]. Analyzing their performance, these KO mice showed an impaired long term memory 
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in the hippocampus, although CREB-1β was expressed there [117]. When the CREB-1α/∆ 
deficient mice were further investigated, it was found that although they were highly expressed, 
CREB-1β and CREM were unable to bind to and transactivate other nuclear transcription factors 
in the absence of CREB-1α and ∆ [118]. This was in contradiction to the initial study of Blendy 
et al. [116], which showed that CREB-1β does have transcriptional activity. However, these 
authors transfected a CREB-1β plasmid into cells, in which the wild-type CREB-1α and ∆ 
isoforms were probably also present. In contrast, in the latter study [118] there was no expression 
of CREB-1α or ∆ at all, which dissolves the apparent inconsistency between the two studies. In 
conclusion, CREB-1β probably has transcriptional activity, but only in the presence of the 
CREB-1α and ∆ isoforms. 
The presence of CREB-1α and ∆ isoforms was verified in more recent studies: For 
example, both isoforms were equally upregulated in hippocampus and cortex of depressive 
transgenic mice model with impaired glucocorticoid receptor function upon antidepressant 
treatment, although the predominant isoform at the mRNA level remained CREB-1∆, consistent 
with the earlier studies [119]. In CREB-1α overexpressing transgenic mice, CREB-1α was 
observed to enhance its own transcription as well. Furthermore, in these animals the expression 
of CREB-1β as well as CREB-1∆ were also increased [120].  
Our results revealed that in C2F3 muscle cells, CREB-1∆ is the predominant isoform at the 
mRNA level, both in myoblasts as well as in myotubes, in accordance with these previous 
studies. However, at the protein level there was a marked shift in the CREB-1α/CREB-1∆ ratio: 
While myoblasts expressed high amounts of CREB-1∆, myotubes switched to the CREB-1α 
isoform (Figure 20A and E). This indicates that in myotubes, in spite of the higher level of 
CREB-1∆ mRNA, an unknown mechanism elevates CREB-1α protein. Hoeffler et al. and 
recently Sato et al. suggested that the regulation of CREB-1 function may take place 
predominantly at the level of translation or by posttranslational modifications [121,122]. 
Irrespective of the isoform, the phosphorylation status was maintained, indicating that the 
isoforms are functionally phosphorylated at Ser-133 as soon as they are available for the 
kinase(s) (Figure 20C and F). 
What is the functional difference between CREB-1α and ∆, why do cells express two 
isoforms and what does a shift mean for CREB-1 function? These questions have not been 
answered yet in spite of 17 years of intensive research. The exon 5 encoded α-domain has a 
proposed α-helical, basic, hydrophobic structure. Disrupting this domain caused a strongly 
decreased activity in driving promoters with CRE sequences and inserting the α-domain into the 
sequence of CREB-1∆ elevates promoter activity compared to the ∆ isoform [109]. The authors 
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hypothesized that the α-domain, due to its basic residues, is able to bind to the phosphorylated 
Ser-133 KID (kinase inducible) domain in the same molecule and thus elevates the 
transcriptional activity of the protein. However, it can function autonomously as well in the 
absence of KID domain through its postulated interaction with other proteins of the 
transcriptional complex [109]. Analyzing the potential posttranslational modifications of the 
mouse CREB-1 protein domain encoded by exon 5 using bioinformatic tools [123], we observed 
two possible serine phosphorylation sites at position 89 and 98, a likely lysine glycosylation site 
at position 94 and one probable YinOYang (O-ß-GlcNAc glycosylation on cytoplasmic/nuclear 
proteins) modification site at position 88. Although the two latter observed modifications are not 
referred yet, CREB-1 was shown to be phosphorylated by many kinases in addition to PKA, such 
as PKC, Akt, Msk, Rsk, p38, CaMKII, CaMKIV and dephosphorylated by multiple 
phosphatases, for example calcineurin (PP2B), PP2A and PP1 (Figure 4). Besides the Ser-133 
phosphorylation, which is essential for the recruitment to CBP/p300, other phosphorylation sites 
are also known, e.g. Ser-142, which was indicated to play a role in entrainment of the 
mammalian circadian clock [124]. Therefore, unique phosphorylation and other modification 
sites of the α domain could play a role in CREB-1α activation, for example by providing new 
docking sites for other transcriptional coactivators.  
5.3.2 CREB-1 activates the cytochrome c promoter 
 To modulate the endogenous level of CREB-1 we used first an siRNA approach. 
However, transfecting any siRNA into C2F3 cells induced an unspecific drop of CREB-1 levels 
as well as a drop in cytochrome c promoter activity (Figure 26 and 27). This phenomenon was 
caused probably by the transfection reagent itself (Figure 26C and D), thus in further 
experiments, constitutive active and dominant negative constructs of CREB-1 were applied to 
promote or inhibit the endogenous CREB-1 activity, respectively. Transfecting the constitutively 
active C2/CREB enhanced promoter activity and the dominant negative A-CREB suppressed this 
upregulation (Figure 28). These results indicate that CREB-1 indeed activates the cytochrome c 
promoter. To verify that CREB-1 directly binds the promoter, the downstream CRE sequence 
had been analyzed in EMSA experiments on nuclear extracts of C2F3 myoblasts and myotubes. 
A specific DNA binding protein-CRE element complex was visible in myoblasts as well as in 
myotubes [32]. Antibodies against CREB-1 or Ser-133 phosphorylated CREB-1 caused a further 
retardation of the DNA binding protein-CRE element complex, suggesting that CREB-1 and P-
CREB-1 binds to the CRE element of cytochrome c promoter in vitro. In addition, chromatin 
immunoprecipitation experiments detected a direct interaction between a fragment of mouse 
cytochrome c promoter containing both CRE elements and CREB-1 and Ser-133 phospho-
                                                                                                                                          Discussion 
CREB-1 in myoblasts, confluent cells and myotubes. CREB-1α was also observed to bind to this 
promoter sequence in confluent cells and myotubes but was completely missing in myoblasts 
[32]. This observation is in agreement with the results of the Western blot analysis, where 
CREB-1α/CREB-1∆ ratio as well as the P133-CREB-1α/P133-CREB-1∆ ratio was the lowest in 
myoblasts but increased in confluent cells and myotubes (Figure 20). According to the results 
mentioned above we set up a model for the interaction of CREB-1 and the cytochrome c 
promoter (Figure 34). In myoblasts, CREB-1∆ is the predominant isoform and binds to the 
downstream CRE element. During myogenesis the level of CREB-1∆ drops in parallel with an 
increase of CREB-1α, which ends up in a situation, where CREB-1α and not CREB-1∆ binds to 
the downstream CRE sequence. We hypothesize that upon different isoform binding different 
transcriptional responses are invoked via CREB-1α or CREB-1∆, respectively. 
 
 
Figure 34. An interaction model of CREB-1 and cytochrome c promoter 
The black line illustrates the DNA sequence of the cytochrome c promoter with chosen cis-elements thought to 
play a role during the process of muscle differentiation. The grey circle represents the RNA II polymerase and 
the arrow shows the transcriptional start site. PGC-1α protein was found to be absent in these cells ([125] and 
data not shown). 
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In conclusion, these results suggest that CREB-1 binds in vitro as well as in vivo to the 
cytochrome c promoter and enhances its activity and that through these effects CREB-1 is 
involved in the regulation of mitochondrial biogenesis during myogenesis. This conclusion 
correlates well with the recently discovered role of the TORCs (transducer of regulated CREB) 
activating PGC-1α upon muscle differentiation [73], and the role of CREB-1 in mitochondrial 
biogenesis induced by mitochondrial dysfunction [67,68,69].  
5.3.3 CREB-1 regulating upstream signals 
In order to study the enzymes, which may modify the activity of CREB-1 by 
phosphorylation or dephosphorylation of Ser-133, PKA activators and inhibitors as well as 
protein phosphatase inhibitors were applied to C2F3 muscle cells. 24 hours treatment with 
Okadaic acid or Cyclosporin A, inhibiting the PP2A or PP2B phosphatases, respectively, 
elevated CREB-1 phosphorylation at Ser-133 (Figure 29 and 30A and B). A specific PKA 
activator, Sp-5,6-DCI-cBIMPS enhanced CREB-1 Ser-133 phosphorylation and Rp-8-CPT-
cAMPS, which is a selective PKA inhibitor, suppressed it (Figure 29 and 30C and D). These 
chemicals were then used in cells transfected with a reporter plasmid to analyze whether these 
interventions could alter the expression of the cytochrome c promoter. Cyclosporin A activated 
the promoter in myoblasts, but the PKA modulating chemicals as well as the PP2A inhibitor 
Okadaic acid did not change significantly the promoter activity, neither in myoblasts nor in 
myotubes (Figure 31). These results indicate that PKA, PP2A and PP2B (calcineurin) are able to 
modify the phosphorylation status of CREB-1 in muscle cells, but reducing the calcineurin 
dephosphorylating step was the only signal, which slightly induced the cytochrome c promoter 
activity, probably via increased CREB-1 phosphorylation. It is known that PP2A, PP2B and 
PKA have several other substrates beside CREB-1, thus for changing the activity of the 
cytochrome c promoter other transcription factors may be needed, which could be regulated as 
well via posttranslational modifications such as phosphorylation. 
 Protein kinase A was the first identified enzyme mediating CREB-1 phosphorylation 
triggered by the increase of cAMP [48]. Later on, new observations suggested that not just 
kinases but also phosphatases are involved in regulating CREB-1 phosphorylation and 
transcriptional activity independently of the level of cAMP. Besides mediating CREB-1 
phosphorylation, these proteins participate in the regulation of myogenesis as well. Initially 
Okadaic acid treatment was shown to block the differentiation of C2C12 cells, when applied in a 
concentration of 62 nM, which is thought to decrease the activity of PP1 phosphatase. A lower 
concentration (6 nM) only counteracting with the activity of PP2A did not affect the 
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differentiation status of the cells [126]. The 5 nM maximum concentration, which was used in 
our study is thus thought to alter only the activity of PP2A, leaving PP1 unaffected [126]. In 
contrast to the altered cell morphology and the increased Ser-133 phosphorylation, 5 nM 
Okadaic acid did not modify the expression of cytochrome c promoter indicating that PP2A 
dephosphorylation of CREB-1 does not play a crucial role in the transcriptional activity of 
CREB-1 in these muscle cells. This idea correlates with the results of Alberts et al. who showed 
that in the NIH3T3 cell line PP1, but not PP2A is the main phosphatase, which alters the 
phosphorylation status and transcriptional activity of CREB-1 [127]. In contrast, another study 
indicated that in liver nuclear extracts PP2A is responsible for the dephosphorylation of CREB-1 
and that it has 30 times higher activity than PP1 [128]. Zákány et al. also showed that 20 nM 
Okadaic acid treatment, which is supposed to block PP2A activity, increased the Ser-133 
phosphorylation of CREB-1 in chicken limb bud cell cultures [129]. Recently, a new 
proteosomal targeting motif was identified in the amino acid sequence of CREB-1 and was 
shown to regulate CREB-1 degradation via serine phosphorylation and ubiquitination. 1 nM 
Okadaic acid was detected to increase the overall serine phosphorylation of CREB-1 
contributing to the phosphorylation status of Ser-133, the proteosomal targeting motif and other 
motifs. These authors postulated that PP1 is the phosphatase responsible for CREB-1 
dephosphorylation [130]. 
In conclusion, both PP1 and PP2A phosphatases are able to dephosphorylate the Ser-133 
phosphate group of CREB-1 in distinct tissues and through this dephosphorylation they change 
the gene regulation activity of CREB-1. At the concentration of Okadaic acid, which was applied 
in the present work, the activity of PP2A was inhibited and since this inhibition increased the 
Ser-133 phosphorylation of CREB-1, this phosphatase seems to be mainly involved in this 
process in our cells. 
 Calcineurin (PP2B) was also shown to be able to dephosphorylate CREB-1. It was 
observed to regulate Ser phosphorylation of the NMDA glutamate receptor, and via this pathway 
increased phosphorylation of Erk1/2 and CREB-1 was detected in the presence of the calcineurin 
inhibitor Cyclosporin A in neurons of rat striatum [131]. In C2C12 cells, 5 µM Cyclosporin A 
enhanced the level of Ser-133 phosphorylated CREB-1 indicating that calcineurin could be an 
upstream CREB-1 modifier in muscle cells as well [132]. Calcineurin not only regulates the 
phosphorylation status of CREB-1 but is also involved in the muscle differentiation program. 
Calcineurin phosphatase activity was demonstrated to be temporally induced at the onset of 
muscle differentiation in C2C12 cells. Overexpression of calcineurin enhanced the number as 
well as the myosin heavy chain expression of differentiated myotubes. [133]. In other studies, 
calcineurin was demonstrated to induce myogenin and myosin heavy chain expression of C2C12 
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cells [134]. This effect of calcineurin was also detected in primary myoblast cultures and L6 
myoblasts investigated by Friday et al. [91]. Nuclear factor of activated T cells (NFATc3) and 
myocyte enhancer factor (MEF2) are other transcription factors regulated by calcineurin 
[133,135]. In C2C12 cells, MEF2 was demonstrated to be activated by calcineurin and by this 
mechanism calcineurin also induced the promoter of PGC-1α, a transcriptional coactivator, 
postulated to participate in the transcriptional complex of the cytochrome c promoter as well. 
However, in this cell line PGC-1α is absent and is thus not a good candidate to be involved in 
transcriptional regulation [125]. A conservative CRE sequence was also found in the promoter of 
PGC-1α and the result of this study indicates that CaMKIV regulates the promoter upon 
activation of CREB-1 [135]. These observations suggest that during enhanced intracellular 
calcium concentration both CaMKIV and calcineurin are activated and work synergistically 
and/or additively together causing elevated PGC-1α promoter activity via CREB-1 and MEF2, 
respectively. A-CREB transfection of C2C12 cells showed a decreased PGC-1α promoter 
activation through CaMKIV and calcineurin, which indicates that CREB-1 is indeed a crucial 
factor for the transactivation of the PGC-1α promoter [135]. In addition, calcineurin was shown 
to regulate the expression of PGC-1α promoter constructs transfected into rat tibialis anterior 
muscle as well. However, overexpression of a constitutive form of calcineurin did not enhance 
the expression of the cytochrome c promoter fragment −326 to +863 [136], which is shorter 
upstream but longer downstream than the promoter sequence used in our study (−631 to +135) 
(Figure 2A). These results suggest that PGC-1α is a good candidate as a transcriptional mediator 
regulated by calcineurin, although the cytochrome c promoter construct analyzed in this study 
[136] lacks possible cis-elements, which could participate in the PGC-1α controlled 
mechanisms. The rat cytochrome c promoter, used in our study, was investigated by a 
transcription factor binding site analysis software (Genomatix, MatInspector) [31] and Figure 2A 
illustrates the cis-elements, which are thought to be involved in muscle specific transcription. 
According to this analysis, a MEF3 binding site is identified in the cytochrome c promoter at 
−355 to −344, which is missing from the promoter sequence studied by Guerfali et al. [136]. 
Since calcineurin modulates the transcriptional activity of MEF2 it could be possible that MEF3 
is also a substrate for calcineurin and in the absence of a MEF3 cis-element, calcineurin is not 
able to modify the cytochrome c promoter activity. Xu et al. demonstrated that calcineurin 
indeed transactivates an artificial promoter containing a MEF3 binding site, although it activated 
the myogenin promoter in the absence of a MEF3 cis-element as well [134]. This shows that 
CREB-1 is not the only transcription factor regulated by calcineurin, and transcription factors 
binding to MEF3 site could be also crucial in the transactivation of the cytochrome c promoter. 
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The fact that the cytochrome c promoter does not contain any MEF2 cis-element consolidates the 
possible importance of MEF3 sequence.  
 In conclusion, CREB-1 is definitely involved in the regulation of the cytochrome c 
promoter. The enzymes, which modulate the phosphorylation status of CREB-1, are not 
completely identified, but PKA, PP2A and calcineurin are good candidates since they are able to 
alter the phosphorylation of CREB-1. As blocking the activity of PP2B increases the 
phosphorylation of CREB-1 (Figure 29 and 30B) and the cytochrome c promoter activity (Figure 
31A), as well as the fact that calcineurin is postulated to regulate muscle differentiation, this 
phosphatase could be a possible key enzyme modulating the effect of CREB-1 in the process of 
mitochondrial biogenesis in myogenic cells.  
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6 Appendix 
Appendix Figure 1. Cloning procedures of AMPKα1-CA into pTRE2Hyg vector 
 
 
 
A and B pTRE2Hyg and pcDNA3-AMPKα1-CA constructs were digested with the illustrated restriction 
enzymes, and the digested DNA fragments were isolated from the gel (dashed rectangles and scissors). C and 
D Test digestions of the pTRE2Hyg-AMPKα1-CA construct verify the presence of AMPKα1-CA insert. The 
pTRE2Hyg-AMPKα1-CA construct or the empty vector was incubated with the illustrated restriction enzymes 
or in their absence (−). M: Molecular weight marker. 
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Appendix Figure 2. Western blot analysis of AMPKα1-CA clones 
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Western blot analysis was performed from protein extracts of AMPKα1-CA expressing C2C12 D3 clones in 
the presence (+) or absence (−) of doxycycline. C2C12, C2C12 D3 or the CA-1 clone, which turned out to be 
not expressing the protein of interest and served as negative controls, CA-27 clone as positive (AMPKα1-CA 
expressing) control. Whitehead arrow shows the endogenous AMPKα and blackhead arrow the AMPKα1-CA 
proteins. The size of molecular weight markers is given in kDa. 
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Dissertation ist von Prof. Dr. Rudolf J. Wiesner betreut worden. 
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